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ABSTRACT OF THE DISSERTATION 
MECHANISMS OF ARSENIC DETOXIFICATION AND RESISTANCE 
by 
Jitesh Kannan Pillai  
Florida International University, 2014 
Miami, Florida 
Professor Barry P. Rosen, Major Professor 
Arsenic is a ubiquitous environmental toxic substance.  As a consequence 
of continual exposure to arsenic, nearly every organism, from Escherichia coli to 
humans have evolved arsenic detoxification pathways.  One of the pathways is 
extrusion of arsenic from inside the cells, thereby conferring resistance.  The 
R773 arsRDABC operon in E. coli encodes an ArsAB efflux pump that confers 
resistance to arsenite.  ArsA is the catalytic subunit of the pump, while ArsB 
forms the oxyanion conducting pathway.  ArsD is an arsenite metallochaperone 
that binds arsenite and transfers it to ArsA.  The interaction of ArsA and ArsD 
allows for resistance to As(III) at environmental concentrations.    
The interaction between ArsA ATPase and ArsD metallochaperone was 
examined.  A quadruple mutant in the arsD gene encoding a 
K2A/K37A/K62A/K104A ArsD is unable to interact with ArsA.  An error-prone 
mutagenesis approach was used to generate random mutations in the arsA gene 
that restored interaction with the quadruple arsD mutant in yeast two-hybrid 
assays.  Three such mutants encoding Q56R, F120I and D137V ArsA were able 
to restore interaction with the quadruple ArsD mutant.  Structural models 
 viii 
 
generated by in silico docking suggest that an electrostatic interface favors 
reversible interaction between ArsA and ArsD.  Mutations in ArsA that propagate 
changes in hydrogen bonding and salt bridges to the ArsA-ArsD interface also 
affect their interactions. 
The second objective was to examine the mechanism of arsenite 
resistance through methylation and subsequent volatilization.  Microbial ArsM 
(As(III) S-adenosylmethyltransferase) catalyzes the formation of trimethylarsine 
as the volatile end product.  The net result is loss of arsenic from cells.  The gene 
for CrArsM from the eukaryotic green alga Chlamydomonas reinhardtii was 
chemically synthesized and expressed in E. coli.  The purified protein catalyzed 
the methylation of arsenite into methyl-, dimethyl- and trimethyl products.   
Synthetic purified CrArsM was crystallized in an unliganded form.  Biochemical 
and biophysical studies conducted on CrArsM sheds new light on the pathways 
of biomethylation.  While in microbes ArsM detoxifies arsenic, the human 
homolog, hAS3MT, converts inorganic arsenic into more toxic and carcinogenic 
forms.  An understanding of the enzymatic mechanism of ArsM will be critical in 
deciphering its parallel roles in arsenic detoxification and carcinogenesis. 
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    CHAPTER I 
Review of the Literature 
Ubiquity of arsenic in the environment and its toxicity 
Arsenic is widely distributed in the Earth's crust and occurs primarily in 
three oxidation states +5, +3, and -3.  Humans are exposed to arsenic from 
mining, copper smelting, coal burning, other combustion processes as well as 
volcanic eruptions that bring arsenic into the environment.  Anthropogenic 
sources of arsenic includes its use in various commonly used herbicides, 
insecticides, rodenticides, wood-preservatives, animal feeds, paints, dyes, and 
semiconductors.  In addition, arsenic enters the food chain from drinking water 
that has flowed through arsenic rich soil.  As a result, arsenic is the most 
ubiquitous environmental toxin and carcinogen according to the U.S. 
Environmental Protection Agency (EPA) and Agency for Toxic Substances and 
Disease Registry (ATSDR), and has consistently ranked first on the ATSDR 
priority list of hazardous substances (http://www.atsdr.cdc.gov/SPL/index.html).   
Chronic exposure to arsenic has been implicated to increased risk of lung, 
bladder, kidney and liver cancers, cardiovascular diseases, peripheral 
neuropathies and diabetes mellitus (Chappell et al., 1997).  Ingestion of arsenic 
predominantly from drinking water can result in skin hyperpigmentation and 
keratosis of the hands and feet that subsequently progress to skin cancers.  In 
countries like Taiwan, Bangladesh and Chile, approximately 10% of such 
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hyperpigmentation and keratosis are associated with a high incidence of lung, 
bladder, and other cancers (Chappell et al., 1997).  Long-term occupational 
exposure to arsenic has been associated with increased prevalence of cancer of 
the buccal cavity, pharynx, lung, kidney, bone, large intestine, and rectum.  
Chronic exposure to arsenic severely compromises the immune response to 
respiratory influenza A (H1N1) virus (Kozul et al., 2009).  In response to new and 
compelling research linking high arsenic levels in drinking water with certain 
forms of cancer, the USEPA lowered the arsenic maximum contaminant level 
(MCL) in drinking water from 50 ppb to 10 ppb (Smith et al., 2002).     
The two biologically relevant oxidation states of arsenic are the 
pentavalent arsenate (As(V)) and trivalent arsenite (As(III)) forms.  In solution the 
pentavalent form, H3AsO4, exists as the oxyanion arsenate, which is a substrate 
analog of phosphate.  Arsenate disrupts phosphorylation reactions by 
substituting for phosphate and eventual formation of unstable arsenyl 
compounds.  The term “arsenolysis” was introduced to describe an over-all 
hydrolytic process in which the first step is the replacement of arsenate for 
phosphate (Doudoroff et al., 1947).  Isotope O18-labeling techniques showed the 
formation of a transient acyl arsenate or arsenate ester intermediate in 
arsenolysis reactions (Slocum and Varner, 1960).  At the substrate level, 
arsenolysis may occur during glycolysis.  In one of the steps of the glycolytic 
pathway, phosphate is linked enzymatically to D-glyceraldehyde-3-phosphate to 
form 1,3-biphospho-D-glycerate.  Arsenate can replace phosphate in this 
reaction to form the anhydride, 1-arsenato-3-phospho-D-glycerate,  which then 
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spontaneously hydrolyses to 3-phosphoglycerate and arsenate thereby reducing 
ATP production of glycolysis from two to zero.  At the mitochondrial level, 
arsenolysis also occurs during oxidative phosphorylation (Moore et al., 1983).  
Depletion of  ATP by arsenate has been observed in rabbit (Delnomdedieu et al., 
1994) and human erythrocytes (Winski and Carter, 1998) after in vitro exposure 
to arsenate. 
Trivalent As(III) are much more toxic than As(V) and is primarily 
responsible for the biological effects of this metalloid.  As(III) has the propensity 
to form strong, nearly covalent bonds with the thiolates of closely spaced 
cysteine residues, thereby inhibiting the function of many proteins.  For example, 
As(III) inhibits the pyruvate dehydrogenase complex by binding to its lipoic acid 
moiety.  As(III) also reacts with other cellular thiols such as reduced glutathione 
(GSH), raising the intracellular redox potential, and leading to oxidative damage. 
Arsenic uptake systems 
Both the pentavalent and trivalent forms of arsenic use uptake systems 
that bring these compounds adventitiously into cells.  As arsenate is a substrate 
analogue of phosphate, most organisms takes up arsenate via the phosphate 
transporters (Figure 1 below).  The prokaryotic microbe, Escherichia coli, has two 
phosphate transporters, Pit and Pst (Rosenberg et al., 1977), both of which 
catalyze arsenate uptake.  Of the two transporters, Pit is the major arsenate 
uptake system (Willsky and Malamy, 1980a, b).  In the eukaryotic microbe, 
Saccharomyces cerevisiae, As(V) enters the cell via the phosphate transporters 
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Pho84 and Pho87 (Bun-Ya et al., 1991; Bun-ya et al., 1996).  In mammalian 
cells, As(V) uptake is mediated by the high-affinity phosphate transporter NaPiIIb 
(Villa-Bellosta and Sorribas, 2010). 
Arsenite in water has a pKa of 9.2 and exists as the undissociated oxyacid, 
As(OH)3, at physiological pH (Ramirez-Solis et al., 2004).  As(OH)3 shows very 
strong similarity with the conformation of glycerol (Porquet and Filella, 2007) and 
is adventitiously taken up by the aquaglyceroporin, GlpF, in E. coli (Figure 1 
below) (Meng et al., 2004; Sanders et al., 1997).  GlpF is a member of the major 
intrinsic protein (MIP) superfamily that allow the transport of water and small 
solutes such as glycerol and urea by an energy independent mechanism. 
Members of the MIP superfamily fall into a number of branches, but the two main 
evolutionary groups are the aquaporins or water specific channels, and the 
aquaglyceroporins, which allow the transport of water, glycerol, and other small, 
uncharged solutes (Mukhopadhyay et al., 2014).  Similarly, Fps1p, the yeast 
homologue of GlpF, conducts arsenite uptake in S. cerevisiae (Wysocki et al., 
2001).  In humans, four aquaglyceroporins conduct As(III) in the order of 
effectiveness AQP9 > AQP7 >> AQP3 >> AQP10 (Liu et al., 2004b). 
A second family of membrane transporters catalyzing arsenite uptake are 
the glucose permeases (Liu et al., 2004a).  In S. cerevisiae, the hexose 
transporters, HXT1, HXT3, HXT4, HXT5, HXT7 and HXT9, allow the adventitious 
uptake of As(OH)3 (Liu et al., 2004a).  The mammalian glucose transporter, 
GLUT1, which is a homologue of the yeast HXT hexose permeases, facilitates 
the uptake of trivalent arsenicals (Liu et al., 2006).  Two other mammalian 
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glucose permeases, GLUT2 in hepatocytes (Drobna et al., 2010) and GLUT5 in 
small intestine (Calatayud et al., 2012), also mediate As(III) accumulation.  
Additionally, OATPB (Calatayud et al., 2012) and OATPC (Lu et al., 2006), two 
human members of the organic anion transporting polypeptide family that 
mediate the transmembrane transport of a wide range of amphipathic 
endogenous and exogenous organic compounds (Hagenbuch and Meier, 2004), 
are also involved in As(III) influx. 
Arsenic extrusion systems 
All living organisms have systems for arsenic detoxification (Figure 1 below).  
The most common detoxification mechanism is either efflux of As(III) from cytosol 
into the external environment or sequestration in an organelle.  Interestingly, all 
identified arsenic efflux systems are for trivalent As(III); none have been reported 
for the pentavalent As(V) form.  Extrusion systems for As(V) do not exist or have 
not been found.  It is postulated that life originated in an anoxic world in the 
presence of high concentrations of heavy metals and metalloids (Zhu et al., 
2014).  On account of a reducing environment, arsenic would have existed as 
As(III) rather than As(V), thereby favoring the evolution of transporters that 
extrude arsenite out of cells.  As the atmosphere became oxidizing, most As(III) 
were oxidized to As(V), and so proteins evolved that reduce arsenate to arsenite, 
the substrate of the existing transport systems.  In prokaryotes, arsenic 
resistance genes are usually organized in ars operons that are controlled by the 
As(III)-responsive transcriptional repressor, ArsR.  Nearly every ars operon has a 
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gene encoding one of the two unrelated families of permeases, ArsB and Acr3.  
ArsB is widespread in bacteria and archaea.  ArsB from plasmid R773 is a 429-
residue membrane protein with twelve membrane spanning segments, which is 
similar to many carrier proteins (Wu et al., 1992).  It is an antiporter catalyzing 
the extrusion of As(III) or Sb(III) from E.coli cells by H+/As(OH)3 exchange that is 
coupled to the electrochemical proton gradient (Meng et al., 2004).  Although 
ArsB transports As(III), it has a higher affinity for Sb(III) in comparison to the 
former (Meng et al., 2004).   
The Acr3 family of arsenic efflux proteins is probably more widespread 
than ArsB and includes members found in bacteria, archaea and fungi.  The first 
identified member of this family is encoded by the ars operon of the skin (sigK 
intervening) element in the chromosome of B. subtilis (Sato and Kobayashi, 
1998).  Fungal members of this family include the S. cerevisiae Acr3p metalloid 
efflux protein (Bobrowicz et al., 1997; Ghosh et al., 1999).  The membrane 
topology of Alkaliphilus metalliredigens AmAcr3-1 shows that, it has ten 
transmembrane spanning segments, with the N- and C-termini localized in the 
cytosol (Fu et al., 2009). Acr3 has been demonstrated to be an antiporter that 
catalyzes arsenite-proton exchange (Villadangos et al., 2012).  Bacterial Acr3 
proteins appear to be specific for As(III) and do not transport Sb(III) (Fu et al., 
2009; Villadangos et al., 2012).  On the other hand, yeast Acr3p has been 
suggested to transport both As(III) and Sb(III) (Maciaszczyk-Dziubinska et al., 
2010). 
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A third class of arsenic permease has recently been reported (Shen et al., 
2014).  The arsP gene is a part of the ars operon in Campylobacter jejuni and 
confers resistance specifically to organoarsenicals, such as roxarsone (4-
hydroxy-3-nitrobenzenearsonic acid) and nitarsone ((4-nitrophenyl) arsonic acid), 
but not inorganic arsenicals, including arsenite and arsenate.  ArsP is predicted  
 
ATP
ADP
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As(V)
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Acr2p
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+ 3 GSH
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Figure 1.  Pathways of arsenical uptake and detoxification in prokaryotes and 
eukaryotes.  As(V) is taken up by phosphate transporters, while As(III) is taken up by 
aquaglyceroporins (GlpF in E. coli, Fps1p in yeast, and AQP7 and AQP9 in mammals), and 
hexose permeases (HXT1, HXT3, HXT4, HXT5, HXT7, or HXT9 in yeast, and GLUT1 and 
GLUT5 in mammals).  In both E. coli and S. cerevisiae, arsenate is reduced to arsenite by the 
bacterial ArsC or yeast Acr2p enzymes.  In both organisms, glutathione and glutaredoxin serve 
as the source of reducing potential.  The proteins responsible for arsenate reduction in 
mammals have not yet been identified.  In E. coli, arsenite is extruded from the cells by ArsB 
alone or by the ArsAB ATPase.  In yeast Acr3p is a plasma membrane arsenite efflux protein, 
and Ycf1p, which is a member of the MRP family of the ABC superfamily of drug-resistance 
pumps, transports As(GS)3 into the vacuole.  In mammals, Mrp isoforms such as Mrp2, pump 
As(GS)3 out of cells. (Rosen et al. 1995). 
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to be a membrane permease containing eight transmembrane helices, distinct 
from other known arsenic transporters.  
In many eukaryotic microbes, multidrug resistance-associated protein 
(MRP) homologues have been shown to confer arsenic resistance.  MRP1 is an 
adenosine triphosphate binding cassette (ABC) transporter that confers multidrug 
resistance in human small cell lung carcinoma (Cole et al., 1994).  The yeast 
protein Ycf1 (yeast cadmium factor), a close homologue of human MRP1, 
catalyzes the vacuolar sequestration of As(III) (Ghosh et al., 1999).  Both MRP1 
and Ycf1 pump glutathione S-conjugated drugs out of the cytosol.  MRP1 
transports arsenic as a tri-glutathione conjugate out of the cell (Leslie et al., 
2004), while Ycf1 catalyzes the ATP-driven uptake of As(III)-glutathione 
conjugate into the yeast vacuole (Ghosh et al., 1999).  In liver, MRP2 extrudes 
arsenic-glutathione complexes into bile and may be a major route of arsenic 
detoxification in humans (Cui et al., 2004).    
Arsenate Reductases  
Cytosolic arsenate reductases catalyze the two electron reduction of 
inorganic As(V) to As(III), which is transported out of the cell by the various 
arsenic transporters, thereby extending the range of resistance to include As(V).  
Arsenate reductases arose independently at least three times by convergent 
evolution and one family of arsenate reductase that includes the E. coli plasmid 
R773 ArsC uses glutaredoxin (Grx) and glutathione (GSH) as reductants 
(Mukhopadhyay and Rosen, 2002).  A second family, represented by the S. 
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aureus plasmid pI258 ArsC (Ji and Silver, 1992) and the B. subtilis chromosomal 
ArsC, uses thioredoxin (Trx) as a reductant.  This bacterial family of arsenate 
reductases is distantly related to mammalian low molecular weight protein 
tyrosine phosphatases (Bennett et al., 2001; Messens et al., 1999).  A third 
family of eukaryotic arsenate reductases includes Acr2p (Bobrowicz et al., 1997; 
Mukhopadhyay and Rosen, 1998) from the Baker’s yeast, S. cerevisiae, and 
LmAcr2p (Zhou et al., 2004) from the parasitic protozoa Leishmania major.  The 
eukaryotic reductases are related to the catalytic domain of the Cdc25 cell-cycle 
protein tyrosine phosphatase (Fauman et al., 1998).  Human Cdc25B and 
Cdc25C also moonlight as arsenate reductase, reducing inorganic arsenate to 
arsenite activity, while using glutaredoxin and glutathione as reductants 
(Bhattacharjee et al., 2010).  
R773 ars operon 
Nearly every sequenced bacterial genome contains an ars operon and the 
minimal gene set in an operon is a three gene arrangement, arsRBC, where 
ArsR is an As(III)-responsive repressor (San Francisco et al., 1990), ArsB is an 
As(OH)3/H+ antiporter (Meng et al., 2004) that extrudes trivalent As(III) from cells, 
and ArsC is an arsenate 
reductase that converts 
As(V) to As(III) 
(Gladysheva et al., 
1994).  Some ars operons contain two additional genes, arsD and arsA, such as 
R D A B C
p ars
Protein ArsR ArsD ArsA ArsB ArsC
Total residues 117 120 583 429 141
Mass (Da) 13,198 13,218 63,188 45,598 15,830
Figure 2.  Organization of E. coli R773 ars operon 
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Figure 3.  A cross section of ars operons representing the coexistence of arsA and 
arsD genes (Lin et al. 2006) 
the arsRDABC operon in E. coli plasmid R773 (Figure 2) (Mobley et al., 1983).  
ArsA is an ATPase that provides energy to ArsB for the extrusion of arsenite and 
antimonite.  ArsD is an arsenic chaperone, which transfers trivalent metalloids 
As(III) and antimonite (Sb(III)) to ArsA.  Interaction with ArsD increases the 
affinity of ArsA for arsenite, thus increasing its ATPase activity at lower 
concentrations of arsenite and enhancing the rate of arsenite extrusion.  These 
cells are consequently resistant to environmental concentrations of arsenic (Lin 
et al., 2006). 
Co-existence of arsA and arsD in ars operons 
Source Representative ars operons
(from about 50 in GeneBank)
Swiss-Prot/TrEMBL 
accession number
Plasmid-encoded arsD arsA
Escherichia coli, 
R773
P46003 P08690
Salmonella typhimurium, 
R64
Q8L253 Q8L248
Klebsiella oxytoca, 
pMH12
Q9KJI4 Q9KJI3
Acidiphilium multivorum, 
pKW301
O50592 O50593
Escherichia coli, 
R46
P52148
(Q79SA7)
P52145
(Q79SA6)
Lactobacillus plantarum, 
pWCFS103 
Q6LWG6
Q6LWG2
Q6LWG5
Rhodococcus erythropolis, 
pREL1
Q3L9K6 Q3L9K5
Rhodococcus erythropolis, 
pBD2
Q6XN06 Q6XN05
Listeria innocua, 
pLI100
Q926M4 Q926M2
Staphylococcus 
saprophyticus, pSSP1
Q49UG6 Q49UG7
Bacillus cereus, 
pBc10987
Q74NT7 Q74NT8
Halobacterium salinarium, 
pNRC100 
O52028 O52027
R D A B C
R D A B C
R D A B C
R D A B C
R D A B C
D AR C B CR
D AB CR C C
R D A B
H
R acr3
B CR RD A
R D AB C
H
RD A C
R D A B HD
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There are more than fifty bacterial and archaeal arsenic resistance operons and 
gene clusters that contain arsA and arsD genes (Figure 3).  It is striking that arsA 
and arsD genes are always found together in ars operons.  The order of the 
genes in those operons may differ from each other, but the arsD gene nearly 
always precedes an arsA gene.  The linkage of these two genes suggests first, 
that ArsD and ArsA co-evolved before their association with ArsB, second that 
the arsDA genes moved laterally into an ars operon as a unit, and third, that 
ArsD has a biochemical function related to ArsA in arsenic detoxification (Lin et 
al., 2007b). 
ArsA ATPase 
The ars operon of R-factor R773 encodes a metalloid extrusion pump that 
confers resistance to As(III) and Sb(III) in E. coli.  This efflux pump has two 
subunits, ArsA and ArsB.  ArsA ATPase is the 63-kDa catalytic subunit of the 
pump.  ArsB is a 45-kDa integral membrane protein that serves as the 
membrane anchor for ArsA and also the oxyanion-translocating sector of the 
pump (Dey et al., 1994).  Arsenic efflux in bacteria can be catalyzed by either 
ArsB alone, functioning as a secondary transporter, or by the ArsAB complex, 
functioning as a transport ATPase (Dey and Rosen, 1995).  E. coli can utilize 
either mode physiologically; however, the ATP-coupled pump is more efficient,  
capable of producing concentration gradients as high as 106, equivalent to a 
concentration of 1 nM intracellular arsenite at 1 mM external arsenite. 
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ArsA is normally bound to ArsB in vivo, but it can be overexpressed and 
purified as a soluble protein from the cytosol (Rosen et al., 1988a).  The soluble 
ArsA exhibits ATPase activity that is stimulated by either As(III) or Sb(III).  The 
583-residue ArsA ATPase has two homologous halves, A1 and A2, connected by 
a short linker.  Each half has a consensus nucleotide binding domain (NBD) and 
both NBDs are required for ATPase activity and oxyanion transport (Karkaria et 
al., 1990; Kaur and Rosen, 1992).  The crystal structure of the MgADP bound 
form of ArsA was determined (Figure 4) at 2.3 Å resolution (Zhou et al., 2000).  
The A1 and A2 halves of the enzyme are related by a pseudo-2-fold axis of 
symmetry.  The two NBDs are in close proximity to each other and are located at 
the A1-A2 interface.  In each NBD, Mg2+ is octahedrally coordinated with the β-
phosphate of ADP, a threonine hydroxyl group, and several water molecules.  In 
the solved structure, the two NBDs appear to be in different conformations 
despite extensive topological similarities, with NBD1 almost completely closed 
and the NBD2 fully open (Zhou et al., 2000, 2001).  To determine the role of each 
NBD in substrate binding and catalysis, a thrombin site was introduced into the 
linker region that connects the A1 and A2 halves.  Following covalent 
radiolabeling with 8-azidoATP and thrombin cleavage, the A1 and A2 halves 
migrated with different mobilities on sodium dodecyl sulfate – polyacrylamide gel 
electrophoresis.  In the absence of metalloid, both NBDs bind and hydrolyze 
ATP.  However, in the presence of metalloid, although both NBDs hydrolyze 
ATP, hydrolysis in NBD1 is stimulated to a much greater extent than NBD2.  
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These experiments suggested that the two homologous halves of ArsA are 
functionally nonequivalent (Jiang et al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
C
Figure 4.  Overall structure of R773 ArsA ATPase (Zhou et al., 2000). The secondary 
structure elements are drawn as cartoon diagram.  The A1 domain is colored in orange and the 
A2 domain in split pea.  The phosphate binding loops (P-loops) are colored cyan.  ADP bound 
in the two NBDs is shown as stick models and colored according to atom type (carbon, sky 
blue; nitrogen, blue; oxygen, red; phosphorus, yellow.  Two stretches of seven residues with 
the identical sequence D142/447TAPTGH148/453 connect the A1 and A2 NBDs with the MBD.  The 
DTAPTGH sequences are shown as stick models and colored as carbon, magenta; nitrogen, 
blue; and oxygen, red.  Bound Sb(III) (purple) and Mg2+ (gray) are shown as space-filling 
models. (Zhou et al, 2000) 
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A novel metalloid binding domain (MBD) is also located at the A1-A2 
interface and is over 20 Å distant from the NBDs.  The MBD contains three 
metalloid atoms: one As(III) or Sb(III) is coordinated to His148 (A1) and Ser420 
(A2), a second to Cys113 (A1) and Cys422 (A2), and the third to Cys172 (A1) 
and His453 (A2) (Zhou et al., 2000).  Kinetic studies indicated that the three 
metalloid atoms bind with different affinities (Walmsley et al., 2001b), suggesting 
that the three metalloid binding sites may allow the pump to operate in different 
ranges of ion concentration.  Each of the amino acid lining the MBD has been 
altered by site directed mutagenesis.  Alteration of Cys113, Cys172, and Cys422 
resulted in substantial loss of metalloid stimulated ATPase activity (Bhattacharjee 
et al., 1995; Bhattacharjee and Rosen, 1996; Ruan et al., 2006, 2008), while 
mutation of His148 and His453 showed a modest decrease in allosteric activation 
of the enzyme (Bhattacharjee and Rosen, 2000).  Cys113 and Cys422 form the 
high affinity metalloid binding site (Ruan et al., 2006).  Although, metalloid 
stimulation of ArsA ATPase activity enhances the ability of the pump to reduce 
the intracellular concentration of oxyanions, high affinity binding of metalloid by 
ArsA is not obligatory for transport or resistance.   
It appears that binding of metalloid to MBD provides an evolutionary 
advantage to survive in low levels of arsenite ubiquitously present in the 
environment (Ruan et al., 2006).  As indicated above, the crystal structure of 
ArsA shows two other bound metalloid atoms, one bound to Cys172 and His453, 
and the other liganded to His148 and Ser420.  The contribution of those putative 
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metalloid sites was examined.  There was little effect of mutagenesis of residues 
His148 and Ser420 on metalloid binding.  However, a C172A ArsA mutant and 
C172A/H453A double mutant exhibited significantly decreased affinity for Sb(III).  
These results suggested that, first, there is only a single high-affinity metalloid 
binding site in ArsA, and second, Cys172 controls the affinity of this site for 
metalloid and hence the efficiency of metalloactivation of the ArsAB efflux pump 
(Ruan et al., 2008). 
The transfer of information of metal occupancy at MBD to the two NBDs is 
performed by two signal transduction domains (STDs).  Two stretches of 
residues, D142TAPTGH148 in A1 STD and D447TAPTGH453 in A2 STD, physically 
connect the MBD to NBD1 and NBD2, respectively.   By introducing tryptophan 
residues in proximity to the D142/447TAPTGH148/453 sequence, conformational 
changes have been observed in response to binding of nucleotide and metalloid 
at the NBDs and MBD, respectively (Zhou et al., 1995; Zhou and Rosen, 1997; 
Zhou et al., 2002).  The roles of Asp142 in A1 D142TAPTGH sequence, and 
Asp447 in A2 D447TAPTGH sequence was investigated after altering the 
aspartates individually to alanine, asparagine, and glutamate by site-directed 
mutagenesis.  The Asp142 mutants were sensitive to As(III) to varying degrees, 
whereas the Asp447 mutants showed the same resistance phenotype as the wild 
type.  Each altered protein exhibited varying levels of both basal and metalloid-
stimulated activity, indicating that neither Asp142 nor Asp447 is essential for 
catalysis.  Biochemical characterization of the altered proteins imply that Asp142 
is involved in Mg2+ binding and also plays a role in signal transduction between 
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the catalytic and activation domains.  In contrast, Asp447 is not nearly as critical 
for Mg2+ binding as Asp142 but appears to be in communication between the 
MBD and NBD.  These results indicate that Asp142 and Asp447, located on the 
A1 and A2 halves of the protein, have different roles in ArsA catalysis 
(Bhattacharjee et al., 2008), consistent with the hypothesis that these two halves 
are functionally nonequivalent.        
The mechanism of allosteric activation of ArsA ATPase has been 
elucidated at the molecular level from a combination of biochemical 
(Bhattacharjee et al., 2000), structural (Zhou et al., 2000, 2001) and kinetic 
experiments (Walmsley et al., 1999, 2001a, b).  In summary, these studies 
indicate that ArsA exists in at least two different conformational forms, where 
bound ATP favors one form and bound metalloids the other.  In the absence of 
activator, the enzyme undergoes a slow conformational change between these 
forms, leading to a lag in attaining maximal steady-state activity.  Binding of 
oxyanions at MBD acts as molecular glue to bring the A1 and A2 halves of ArsA 
together and enhances the steady-state ATPase activity by inducing rapid 
product release and allowing the protein to adopt a conformation that can bind 
MgATP for the next catalytic cycle.  In the presence of activator, ArsA avoids the 
rate-limiting isomerization at the end of the ATPase reaction and now ATP 
hydrolysis becomes rate-limiting for the reaction.  When ArsA is bound to ArsB, 
the complex probably functions as a reciprocating engine, where cytosolic 
As(III)/Sb(III) accesses the high affinity metalloid binding site of ArsA.  ATP 
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hydrolysis is linked with step wise transfer of the metalloid to the low affinity sites, 
followed by vectorial transport of metalloid into ArsB (Zhou et al., 2001).  
ArsD 
The R773 ArsD, a 120-residue polypeptide, was originally identified as a 
weak As(III)-responsive transcriptional repressor (Chen and Rosen, 1997).  
Since its regulatory properties are so poor, it is questionable whether that is the 
primary function of ArsD.  More recently, ArsD has been shown to be a metalloid 
chaperone that delivers As(III) to ArsA, increasing ArsA’s affinity for As(III), thus 
conferring resistance to environmental concentrations of arsenic (Lin et al., 
2006).  Without ArsD, ArsAB pump can only work in very high concentrations of 
As(III) found in extreme environments (Lin et al., 2006). 
Evidence of physical interaction between ArsD and ArsA 
ArsA and arsD genes are located in tandem in many ars operons, it suggests co-
evolution for a common function, most likely arsenic detoxification.  Cells 
coexpressing arsDAB are more resistant to As(III) (IC50 = 13 mM) compared to 
cells expressing only arsAB (IC50 = 9 mM) (Lin et al., 2007a).  In a molecular 
competition experiment designed to resemble environmental conditions, a culture 
of cells of E. coli expressing either arsDAB or arsAB were mixed and grown at 10 
μM arsenite, a sub-toxic concentration that is found in many of the arsenic-
contaminated regions of the world.  After a week, the only cells remaining had all 
three genes, arsDAB.  Thus, having an arsD gene gives bacteria a competitive 
advantage over cells having only arsAB while growing in sub-toxic concentrations 
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of arsenic.  Additionally, cells expressing arsDAB accumulate less As(III) than 
those expressing only arsAB (Lin et al., 2006).  The above observations suggest 
that ArsD acts to increase the efficiency of arsenic extrusion by the ArsAB pump 
and also implies that the two proteins must physically interact. 
The interaction of ArsA and ArsD was demonstrated by yeast two-hybrid 
analysis (Lin et al., 2006).  Among the four soluble proteins encoded by the R773 
arsRDABC operon, ArsD was shown to interact with itself (as ArsD is a 
homodimer) and with ArsA.  ArsD did not interact with either the ArsR repressor 
or the ArsC arsenate reductase.  Conversely, ArsA interacted with ArsD only. 
Notably no As(III) or Sb(III) was added to the yeast culture media, indicating that 
ArsD and ArsA interact to some extent in the absence of added metalloid. 
Chemical cross-linking with dibromobimane has shown that the metalloid 
binding sites of ArsA and ArsD come together within 6 Å of each other during 
interaction.  This crosslinking was increased upon addition of MgATP which 
means there is increased interaction between the ArsD and the nucleotide bound 
form of ArsA (Lin et al., 2006). 
Proposed mechanism of metalloid transfer from ArsD to ArsA 
Native ArsD has 3 vicinal cysteine pairs, Cys12-Cys13, Cys112-Cys113 
and Cys119-Cys120.  Each of the vicinal cysteine pairs form a metalloid binding 
site (Li et al., 2001) and binds Sb(III) with a Kd of approximately 1 µM (Lin et al., 
2007a).  When homologues of ArsD are aligned with R773 ArsD, only the Cys12, 
Cys13 and Cys18 are absolutely conserved and these three cysteines were 
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found to be critical for metalloid binding (Lin et al., 2007a).  A construct of R773 
ArsD with truncation at 109th residue (ArsD109) was used to perform Extended X-
ray Absorption Fine Structure (EXAFS) studies, which showed that Cys12, Cys13 
and Cys18 form a three-coordinate thiol system for As(III) binding.  A tryptophan-
free construct based on the ArsD109 construct was made and tryptophan inserted 
near the metalloid binding site was used to study binding with As(III) and Sb(III). 
The Kd of As(III) binding to ArsD was measured to be ~2 µM with either the T15W 
or V17W ArsD (Yang et al., 2010). 
An assay to measure transfer of As(III) from ArsD was designed in which 
ArsD with a maltose binding protein tag (MBP-tag) was pre-incubated with As(III) 
and bound to an amylose column and excess As(III) was washed from the 
column.  Next, ArsA was passed through the column in various conditions to see 
if ArsD is able to transfer the As(III) to ArsA.  The protein concentration and 
As(III) concentration of ArsA eluents were determined.  The results showed that 
ArsD transfers As(III) to ArsA in presence of MgATP at room temperature but not 
at 4oC.  Metalloid transfer does not occur in the presence of MgADP or the non-
hydrolysable nucleotides, MgATPγS or MgAMP-PNP which means that ATP 
hydrolysis is required for As(III) transfer from ArsD to ArsA (Yang et al., 2010).  It 
is inferred that As(III) transfer takes place in a conformation of ArsA attained 
during ATP hydrolysis.   
The metalloid transfer could have taken place, either by dissociation of 
As(III) from ArsD and then binding to ArsA or by direct transfer from ArsD to 
ArsA.  The ATPase assay was carried out in presence of meso-2,3-
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dimercaptosuccinic acid (DMSA) which is a strong chelator of  free As(III).  ArsD 
was able to stimulate ArsA showing that transfer is direct (Yang et al., 2010).  
ArsD increases the affinity of ArsA for As(III) from millimolar to micromolar range 
(Lin et al., 2006).   The affinity of ArsD for As(III) is greater than that for ArsA.  
Hence, it does not seem likely that As(III) transfer from ArsD to ArsA can be 
explained by free dissociation of As(III) from ArsD.  However, it is likely that the 
energy of ATP hydrolysis at NBD of ArsA coupled with mass action of As(III) 
efflux from cell should explain the transfer of As(III) from ArsD to ArsA. 
ApoArsD has been crystallized as wild type and cysteine free derivatives 
(Figure 5) (Ye et al., 
N
C
C
N
Figure 5.  Crystal structure of ArsD dimer (Ye et al., 2010) 
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2010).  Wild type ArsD crystals were determined to 2.1 Å resolution in X-ray data 
collection whereas the cysteine free mutant was solved  
to 1.4 Å.  The ArsD monomer has a core of four β-strands flanked by four α-
helices with a thioredoxin fold (PDB ID 3MWH).  ArsD aligns with E.coli 
thioredoxin TrxA (PDB ID 2TRX) with a RMSD (root mean square deviation) of 
2.5 Å between the Cα atoms of the 72 aligned residues.  The active site cysteine 
residues of TrxA are not congruent with Cys12, Cys13 or Cys18 in ArsD 
indicating that the As(III) binding site evolved independently.  Nuclear Magnetic 
Resonance Spectroscopy (NMR) solution structure determination of ArsD was 
carried out to identify amino-acid specific chemical environmental changes in 
ArsD coupled with binding of As(III) or Sb(III).  High resolution 15N TROSY HSQC 
(15N Transverse Relaxation Optimized Spectroscopy with Heteronuclear Single 
Quantum Coherence Spectroscopy) spectrum indicates that the protein is well-
folded with the number of peaks consistent with the protein existing as a 
symmetric homodimer (Ye et al., 2011). Partial assignments were made for the 
protein residues.  The predicted secondary structure in solution is in reasonable 
agreement with the crystal structure with only a few differences.  The structure of 
oxidized orthologue of ArsD (PDB ID 3KTB) has allowed modeling of the arsenic 
binding loop. PDB ID 3KTB’s 2.1 Å structure can be superimposed with a RMSD 
of 1 Å.  The 11-residue metalloid binding loop of ArsD is present as a 14-residue 
loop in 3KTB with intermolecular and intramolecular disulfide bonds.  The 
distances of 2.24 Å between As(III) and cysteines was determined from EXAFS 
(Extended X-ray Absorption Fine Structure) studies (Yang et al., 2010). 
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Metal bound ArsD interacts with ArsA as it alternates between open and 
closed conformations during its catalytic cycle (Figure 6) (Li and Rosen, 2000).  
The crystal structure of the closed form of ArsA has been obtained (Zhou et al., 
2000).  The open form of ArsA has been modeled based on the Get3 homolog of 
ArsA in yeast which is involved in targeting tail-anchored proteins in the 
endoplasmic reticulum (Auld et al., 2006).  Get3 has been crystallized in open 
(nucleotide free) and closed conformations (ADP.AlF4- bound) (Bozkurt et al., 
2009; Mateja et al., 2009).  The NBD1 and NBD2 of ArsA was superimposed with 
the two monomers in Get3 open structure with RMSD of 2.3 Å and 3.0 Å, 
respectively.  Thus, an open model of ArsA based on the open Get3 structure 
was generated which was used to examine if ArsA and ArsD have 
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Figure 6. Proposed mechanism of metalloid transfer between ArsD and ArsA.  ArsA 
alternates between open and closed conformations accepting As(III) from ArsD and 
translocating it out of the cell with the help of ArsB (not shown in figure) while expending ATP 
(Lin et al., 2007a). 
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complementary surfaces using web based ClusPro version 2.0.  Out of the 108 
top-scoring results from ClusPro docking server, one model had ArsD fitting into 
ArsA and showing close proximity between cysteine residues of ArsD and ArsA 
corroborating with the biochemical data of ArsA and ArsD metalloid binding sites 
(Ye et al., 2010).  A separate yeast two hybrid study of ArsA and ArsD mutants 
corroborated with the residues found in the docking study (Yang et al., 2010) .    
The arsenic chaperone, ArsD, is the first and, to date, only example of a 
metallochaperone that protects the cell from metal toxicity.  Traditionally, 
metallochaperones ensure the safe delivery of the metal ion to its proper 
intracellular destination, guiding and protecting the metal ion, while facilitating 
appropriate partnerships (O'Halloran and Culotta, 2000).  These include 
prokaryotic and eukaryotic metallochaperones for copper (Palumaa, 2013) and 
iron (Philpott, 2012), and prokaryotic nickel (Ge et al., 2013) chaperones. 
Although extensive research have been carried out on both the structural 
details of ArsA and ArsD and their biochemical roles, limited work has been 
performed to understand and identify the surface residues of ArsA interacting 
with ArsD.  Chapter II of this dissertation discusses the experiments conducted to 
examine the interaction between ArsA and ArsD. 
Biomethylation and its importance 
Biomethylation is one of the common transformations observed in nature.  
It is the addition of a methyl moiety to an atom.  Methylation modulates the 
bioavailability, bioactivity and reactivity of acceptor atoms and the most common 
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methyl accepting atoms are C, O, N and S (Liscombe et al., 2012).  Addition of 
methyl group is done enzymatically and requires an activated methyl group.  One 
of the most common activated methyl group used by organisms is the one found 
in S-adenosylmethionine (SAM).  SAM is a conjugate of methionine and 
adenosine moiety of ATP formed in an enzyme catalyzed reaction by methionine 
adenosyl transferase.  SAM is one of the most used metabolic substrates after 
ATP (Loenen, 2006).  The chemical reactivity of SAM is a consequence of the 
electrophilic nature of its methyl group beside the sulfonium center (Fontecave et 
al., 2004).  SAM may have predated life itself on earth as a result of experiments 
showing that the basic reactions required for SAM synthesis could have been 
possible in the early earth environment (Waddell et al., 2000).  The favorable 
thermodynamics associated with SAM is responsible for it becoming the second 
most used substrate after ATP.  The SAM reaction proceeds mostly by a SN2 
type mechanism with the methionine sulfur as the nucleophile and the substrate 
atom as the electrophile (Scavetta et al., 2000).  SAM is the methyl donor for a 
wide variety of biological molecules like DNA, RNA, histones and proteins.  The 
reactions with these biological molecules are important for replication, 
transcription, DNA repair and epigenetic modifications.   
Imbalance of methionine cycle for SAM recycling can cause human 
disease.  One of the primary sources of the methyl group for humans is folate 
from foodstuffs.  Low levels of serum folate, high levels of plasma homocysteine 
and polymorphisms in the MTHF receptor are implicated in SAM depletion and a 
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wide range of diseases (Coppen and Bolander-Gouaille, 2005; Ulrey et al., 
2005).  The natural product methyltransferases  are SAM methyltransferases 
found in plants which are responsible for methylation of phenolics, catechols, 
hexoses, non-ribosomal peptides, hexosamines, primary, secondary and tertiary 
amines, and are also involved in caffeine biosysnthesis (Liscombe et al., 2012). 
Evolution of methyltransferases 
Early sequence alignments of SAM dependent methyltransferases 
showed the presence of three motifs that were found to be common to this class 
of protein ( Figure 7) (Martin and McMillan, 2002).  The conserved sequences 
were predicted to contribute in binding of the substrate SAM and/or the product 
S-adenosylhomocysteine (SAH).  Some of the motifs were also identified in 
certain nonmethyltransferases like SAM synthetase and SAH hydrolase (Kagan 
and Clarke, 1994).  SAM methyltransferases show both functional divergence 
 
Figure 7.  Topology of the core fold of SAM methyltransferases with SAM and substrate 
binding fold.  Yellow cylinders are helices and red arrows are β-strands (Martin and McMillan, 
2002). 
 26 
 
and convergence in its evolution.  The Rossmann fold and 
triosephosphateisomerase (TIM) barrel have been repeatedly used for different 
types of SAM conversion during evolution.  The Rossmann fold is a protein 
spatial structure consisting of alternating β pleated sheets and α helices, the β 
pleated sheets forming a central planar sheet and the helices filling two layers, 
one on each side of the plane (Kozbial and Mushegian, 2005).  The functionally 
important conserved residues are often located in the C terminus of the β-strands 
or in the loops adjoining the β-strands (Lesk, 1995). There are six highly 
conserved regions of SAM binding region which have been categorized as motif I 
through VI.  The important features of which have been summarized in Table 1. 
Table 1.  Conserved motifs of SAM methyltransferases (Kozbial and Mushegian, 2005) 
Motifs Characteristics 
I 
GXGXG conserved in the C-terminal and is hallmark SAM-binding site of 
Rossmann-fold SAM-dependent methyltransferases.  Well-conserved 
aspartate or glutamine residue in middle of β-strand 1 and positively 
charged residue/residues close to the N-terminus of this β-strand. 
II Includes β-strand 2 and adjoining turn.  Partially conserved acidic residue at 
the C-terminus of the strand. 
III Corresponds to Motif III and located at edge of Rossmann fold’s β-sheet 
IV β-strand 4 and flanking loops with a conserved aspartate/ glutamate/ 
asparagine residue located at the extreme N-terminus of the strand 
V Helix after motif IV 
VI β-strand 5 
Arsenic biomethylation 
Biomethylation of arsenic is widespread and occurs in all three domains of 
life, bacteria, archaea and eukaryota (Sumi and Himeno, 2012; Ye et al., 2012).  
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The first example of biomethylation of a metalloid was given by the Italian 
physician Bartolomeo Gosio in the 1890s, who described the production of a 
toxic, arsenic gas with a garlic-like odor (hence the name “Gosio gas”) from 
various fungi, when they were grown on organic matter or soil samples 
containing arsenic compounds.  Frederick Challenger demonstrated that Gosio 
gas is trimethylarsine, (CH3)3As or TMAs(III) (Challenger and Higginbottom, 
1935).  In 2002, Thomas and colleagues identified an As(III)-methyltransferase 
(As3MT) from rat liver cytosol as an enzyme responsible for arsenic methylation 
(Lin et al., 2002). 
 While the molecular mechanisms of arsenic biomethylation have been 
studied intensively over the past few years, many of the mechanistic details of 
the pathway are still elusive.  Challenger proposed a scheme in which arsenate 
can be converted to TMAs(III) (Figure 8) via a series of alternating reduction and 
oxidative methylation (Challenger, 1947, 1951).  At the time the Challenger 
mechanism was proposed, neither the methyl donor nor the reducing equivalents 
were known. Later, it was generally accepted that SAM is the methyl donor.  The 
starting species in the Challenger pathway (also known as the classical pathway) 
is As(V) and then in each successive step, there is the reduction of pentavalent 
arsenic species to trivalent species followed by an oxidative methylation by SAM 
to obtain the methylated pentavalent form.  In all, As(III) undergoes four 
reductions and three methylations to form TMAs(III).  The pentavalent arsenical 
species in the Challenger pathway are As(V), MAs(V), DMAs(V), TMAs(V)O and 
the trivalent species are As(III), MAs(III), DMAs(III) and TMAs(III). 
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 While many of the arsenic species proposed by the Challenger pathway 
were identified, it was also observed that metabolism of As(III) in rat liver leads to 
the excretion of arsenic-glutathione (As-GSH) complexes, such as arsenic 
triglutathione, As(GS)3, and monomethylarsenic diglutathione, MAs(GS)2, in bile 
(Kala et al., 2000).  These arsenicals were not described in the Challenger 
pathway.  To address this anomaly, Hirano and his group (Hayakawa et al., 
2005) proposed an alternate metabolic pathway in which glutathione conjugation 
of As(III) occurs first to form As(GS)3, followed by methylation of As(GS)3 in the 
presence of SAM to yield MAs(GS)2.  MAs(GS)2 is subsequently methylated to 
dimethylarsinic glutathione, DMAsSG.  Depending on GSH concentration, 
Reduction
Oxidative methylation
As(V)
As(III)
HO-As=O
OH
O-
HO-As-OH
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MAs(V)
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CH3
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DMAs(V)
H3C-As-OH
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Figure 8.  The Challenger’s pathway for reductive methylation of inorganic As(V) into 
volatile, organic TMA(III). 
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MAs(GS)2 and DMAsSG are in equilibrium with MAs(III) and DMAs(III), 
respectively, which may oxidize non-enzymatically or after exposure to air to 
MAs(V) and DMAs(V), the observed urinary species (Hayakawa et al., 2005). 
The bacterial homologue of As3MT, designated as ArsM, has been 
observed in a number of ars operons and under the control of ArsR repressor, 
suggesting that ArsM might have a role in arsenic resistance.  ArsM from 
Rhodopseudomonas palustris has been shown to confer As(III) resistance when 
expressed in ∆ars E. coli (Qin et al., 2006).  Further chemical speciation analysis 
showed that the purified enzyme in the presence of SAM and GSH can convert 
As(III) to DMAs(V) and TMAs(V)O and finally TMAs(III) gas.  Methylation of 
As(III) by ArsM resulted in the loss of arsenic from both the medium and the cells 
through volatilization. Therefore, methylation may also be considered a 
detoxifying process.   
Whether arsenic biomethylation is a pathway of detoxification is still being 
debated.  Some of the intermediate products, MAs(III) and DMAs(III), are more 
toxic than As(III) (Hirano and Kobayashi, 2006; Sakurai et al., 2006; Styblo et al., 
2000).  However, the pentavalent intermediate products, MAs(V) and DMAs(V), 
are much less toxic than As(III) (Styblo et al., 2000), and the end product, 
TMA(III), is almost nontoxic (Cullen, 2005).  Research on the biomethylation of 
arsenic by bacteria and mammals have provided an understanding of some of 
the molecular processes.  However, less is known about these processes in 
cyanobacteria and algae, and almost nothing is known in higher plants.  No 
enzyme responsible for arsenic methylation has been found in plants.  Therefore, 
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understanding the mechanism is the first step to harnessing the biomethylation 
process for bioremediation and the production of safe food. 
Knowledge of enzymatic mechanism can only be acquired from studies 
with purified enzyme.  One of the objectives of my research was to perform 
structure-function analysis of an AS3MT orthologue, Chlamydomonas reinhardtii 
ArsM (CrArsM) and is described in Chapter III.   
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CHAPTER II 
Genetic mapping of the interface between the ArsA ATPase and ArsD 
metallochaperone 
Introduction 
Arsenic is a ubiquitous environmental toxic substance and enters the 
environment from both geochemical and anthropogenic sources.  The Agency for 
Toxic Substances and Disease Registry puts arsenic at the top of its Substance 
Priority List (http://www.atsdr.cdc.gov/spl/) because this metalloid poses the most 
significant potential threat to human health due to its toxicity and potential for 
human exposure.  In humans, exposure to arsenic is associated with a number of 
diseases, including several forms of cancer, cardiovascular disease, peripheral 
neuropathies and diabetes mellitus (Abernathy et al., 1999; Beane Freeman et 
al., 2004).  As a consequence of continual exposure to arsenic, nearly every 
organism, from Escherichia coli to humans, has evolved pathways for arsenic 
detoxification (Zhu et al., 2014).  The arsRDABC operon of E. coli plasmid R773 
encodes five genes for arsenic detoxification (Chen et al., 1986; San Francisco et 
al., 1990).  The ArsAB complex is an efflux pump that confers resistance to 
arsenicals and antimonials.  ArsA is the catalytic subunit of the pump that 
hydrolyzes ATP in the presence of As(III) or Sb(III) (Hsu and Rosen, 1989). The 
ATP hydrolysis is coupled to extrusion of As(III) or Sb(III) through ArsB, which 
serves both as a membrane anchor for ArsA and as the substrate-conducting 
pathway (Tisa and Rosen, 1990).  ArsD is an As(III) metallochaperone that 
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interacts with ArsA to increase arsenic resistance (Lin et al., 2006).  Purified 
ArsD binds As(III) and transfers it to ArsA, stimulating its ATPase activity (Lin et 
al., 2006; Yang et al., 2010).  The apo structure of ArsA (Zhou et al., 2000) and 
ArsD (Ye et al., 2010) have each been determined by x-ray crystallography, and 
structural models of the As(III)-bound forms of both protein and the ArsD-ArsA 
complex have been constructed (Ye et al., 2010).   
A yeast two-hybrid genetic mapping approach identified seventeen 
residues of ArsD that either enhance or reduce interaction with ArsA (Yang et al., 
2011).  These residues included Cys12, Cys13 and Cys18, which form the As(III) 
binding site, and a series of N-terminal residues that form a spine along the 
surface of the protein.  Independently, an in silico docking model (Ye et al., 2010) 
identified many of the same residues obtained from the genetic mapping studies, 
suggesting that ArsD and ArsA interact at an interface between the two proteins 
(Yang et al., 2011). 
ArsD has six lysine residues at positions 2, 37, 60, 62, 90, and 104.  The 
quadruple lysine mutant K2A/K37A/K62A/K104A of ArsD (4KA ArsD) did not 
interact with wild type ArsA in yeast two hybrid studies and also was not able to 
stimulate ATPase activity in wild type ArsA (Yang et al., 2011).  The metalloid 
binding ability of 4KA ArsD was determined to be similar as the wild type (Yang 
et al., 2011).  In contrast, the quadruple K2A/K37R/K62R/K104A ArsD derivative 
stimulated ArsA activity nearly as well as wild type ArsD.  In the 100 closest ArsD 
homologues in the NCBI database, residue 37 is either lysine or arginine, and 
residue 62 is always lysine (Yang et al., 2011).  These observations suggested 
 33 
 
that alanine substitutions in ArsD abolish its interaction with ArsA, but arginine 
substitutions are permitted in Lys37 and Lys62.     
As mentioned above, ArsD has a dual role: first, transfer of metalloids 
from ArsD to ArsA and second, to enhance the catalytic activity of ArsA.  
Although extensive research have been carried out on both the structural details 
of ArsA and ArsD and their biochemical roles, limited studies have been 
performed to understand and identify residues of ArsA that either directly interact 
with ArsD or indirectly facilitate interaction.  In the present study, the interaction 
between ArsA and ArsD was further examined by screening for suppressor 
mutants of ArsA that interact with 4KA ArsD. 
Materials and methods 
Reagents 
3-Amino-1, 2, 4-triazole (3-AT) was purchased from MP Biomedicals (Solon, 
OH).  5-Fluoroorotic Acid (5-FOA) was purchased from Thermo Scientific 
(Pittsburgh, PA).  Yeast Minimal Media-SD Base and Amino Acid Dropout Mixes 
(-Leu/-Trp and -His/-Leu/-Trp) were purchased from Clontech (Mountain View, 
CA).  Unless otherwise mentioned, all other chemicals were obtained from 
Sigma-Aldrich (St. Louis, MO). 
Strains, plasmids and media 
E. coli strain JM109 was used for molecular cloning (Table 2).  E. coli strain 
BL21(DE3) was used for protein expression and purification.  The arsA gene with  
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Table 2.  Strains and plasmids 
Strains/Plasmids Genotype/description Reference 
E.coli strains   
JM109 e14-(McrA-) recA1 endA1 gyrA96 thi-1 hsdR17 (rK- 
mK+) supE44 relA1 ∆(lac-proAB) [F’ traD36 proAB 
lacIq Z∆M15] 
(Green et al., 
2012) 
BL21(DE3) fhuA2 [lon] ompT gal (λ DE3) [dcm] ∆hsdS λ DE3 =  
λ sBamHIo ∆EcoRI-B int::(lacI::PlacUV5::T7 gene1) 
i21 ∆nin5 
(Green et al., 
2012) 
S. cerevisiae strains   
AH109 MATa, trp1-901, leu2-3, 112, ura3-52, his3-200, 
gal4∆, gal80∆, LYS2 : : GAL1UAS-GAL1TATA-HIS3, 
GAL2UAS-GAL2TATA-ADE2, URA3 : : MEL1UAS-
MEL1TATA-lacZ 
Clontech 
Plasmids   
pACT2 GAL4(768-881) activation domain, LEU2 (Apr) Clontech 
pGBT9 GAL4(1-147) DNA-binding domain, TRP1 (Apr) Clontech 
pAD-A arsA gene cloned in pACT2 (Apr) (Lin et al., 
2006) 
pBD-k Kanamycin resistance gene PCR amplified from 
pET28a and inserted into pGBT9 at AatII site (Knr) 
(Yang et al., 
2011) 
pBD-k-D Kanamycin resistance gene PCR amplified from 
pET28a and inserted into pBD-D at AatII site (Knr) 
(Yang et al., 
2011) 
pBD-k-4KA DNA fragment encoding ArsD mutation 
K2A/K37A/K62A/K104A inserted into pBD-k (Knr) at 
the EcoRI and BamHI sites. 
(Yang et al., 
2011) 
pAD-AX Single mutations (X) Q56R, V90F, T115K, F120I, 
V190I, K404R, and E506G separately introduced by 
site-directed mutagenesis into pAD-A 
This study 
pETy-dAhB arsA cloned into pET28a with six histidine tags at 
the C-terminus 
(Lin et al., 
2006) 
pETy-dAxhB Single mutations (X) Q56R, F120I, D137V 
separately introduced by site directed mutagenesis 
into pETy-dAhB 
This study 
 
pET28a Expression vector for his-tagged proteins controlled 
by T7 promoter (Knr) 
Novagen 
 
pET28a-ArsD109 arsD1-109 truncation inserted into pET28a at EcoRI 
and SalI sites (Knr) 
(Yang et al., 
2011) 
pET28a-
ArsD109K2A/K37A/K62A/K104A 
Mutations K2A/K37A/K62A/K104A constructed by 
site directed mutagenesis into pET28a-ArsD109 
(Knr ) 
(Yang et al., 
2011) 
 35 
 
a C-terminal six-histidine tag was cloned into the expression vector pET-28a as 
pETy-dAhB (Lin et al., 2006).  Two forms of ArsD were used in this study.  The 
gene for full-length wild type arsD was used in yeast two-hybrid analyses.  All 
biochemical assays were performed with a fully active ArsD that is C-terminally 
truncated at residue 109 with a six-histidine tag (termed simply ArsD in this 
study). The gene for this ArsD was cloned in the expression vector pET28a as 
pET28a-ArsD109.  E. coli cells were grown at 37 °C in Luria-Bertani (LB) medium 
(Green et al., 2012).  Ampicillin (100 μg/ml), kanamycin (40 μg/ml) and 0.3 mM 
isopropyl-ß-D-thiogalactopyranoside (IPTG) were added as required.  Yeast cells 
were grown in complete yeast extract-peptone-dextrose (YPD) or minimal 
synthetic dextrose (SD) media with the appropriate supplements at 30 °C 
(Adams et al., 1998).  Growth in liquid culture was estimated from the optical 
density at 600 nm. 
DNA manipulation and mutagenesis 
Plasmid extraction, DNA restriction endonuclease analysis, ligation and other 
general molecular biological procedures were performed as described (Green et 
al., 2012).  Transformation of E. coli cells was carried out using a MicroPulser 
Electroporator (Bio-Rad, Hercules, CA).  Transformation of yeast cells was 
performed using Fast Yeast Transformation kit from G-Biosciences (St. Louis, 
MO).  DNA purification kits were purchased from Qiagen (Valencia, CA).  Either a 
Qiaprep Spin Miniprep kit or a Qiaquick Gel Extraction kit was used to prepare 
plasmid DNA for restriction enzyme digestion, sequencing, and recovering DNA 
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fragments from agarose gels.  Single mutants of arsA were made in pACT2-ArsA 
construct by site-directed mutagenesis using QuikChange Site-Directed 
Mutagenesis Kit from Agilent Technologies (Santa Clara, CA).  The sequence of 
new plasmid constructs was confirmed by DNA sequencing using Sequetech 
DNA Sequencing Services (Mountain View, CA). 
Generation of a random mutated library of PCR fragments 
Random mutagenesis of arsA was performed using error-prone (ep)-PCR 
employing biased nucleotide composition of the PCR buffer, increasing the 
concentration of Mg2+, and addition of Mn2+ to the reaction mixture (Cadwell and 
Joyce, 1992).  The ep-PCR reaction mixture (50 μl) contained 20 mM Tris-HCl 
(pH 8.4), 50 mM KCl, 7 mM MgCl2, 0.5 mM MnCl2, 0.2 mM each of dATP and 
dGTP, 1 mM each of dCTP and dTTP, 25 pmol each of the oligonucleotide 
primers (forward, CTA TTC GAT GAT GAA GAT ACC CCA CCA AAC CC; 
reverse, AGG TTA CAT GGC CAA GAT TGA AAC TTA GAG GAG), 80 ng of 
template DNA, 2.5 U of Taq DNA polymerase (Life Technologies).  The PCR 
condition was 1 cycle of 96 °C for 3 min, 30 cycles of 94 °C for 30 s, 55 °C for 30 
s, and 72 °C for 100 s, and, finally, 1 cycle of 72 °C for 10 min.  The ep-PCR 
product was purified by agarose gel and quantified by absorption at 260 nm. 
Yeast two-hybrid analysis 
Plasmids pGBT9 and pACT2 were used as S. cerevisiae / E. coli shuttle vectors 
for yeast two-hybrid assay (Lin et al., 2006).  The yeast strain, AH109 (Fields and 
Song, 1989) was used for yeast two-hybrid assays which is a GAL4-based yeast 
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two-hybrid system.  AH109 was used to analyze protein-protein interaction or for 
selection of mutants retaining capability of interaction or showing stronger 
interaction in the presence of 3-AT.  The plasmid pGBT9 was modified to pBD-k 
by inserting kanamycin resistance gene through AatII site (Yang et al., 2011).  To 
determine protein-protein interaction by growth of serial dilutions, the transformed 
cells were cultured overnight in SD medium at 30 °C, centrifuged at 10,000 g, 
and the pellets were washed with 20 mM Tris-HCl (pH 7.5) and adjusted to an 
OD600 of 1.  Portions of the cell suspension (1 μl) were inoculated in serial 10-
fold dilutions on SD agar plates lacking histidine or with 3-AT at the indicated 
concentration.  The plates were incubated at 30 °C for 3 days.   
Sequencing of arsA mutant genes in yeast colonies 
Each yeast colony was grown in SD medium.  The plasmids were isolated from 
yeast by ZymoprepTM Yeast Plasmid Miniprep II kit (Zymo Research Corporation, 
Irvine, CA), transformed to E. coli JM109 and grown on LB plates with ampicillin.  
The plasmids were extracted from E. coli JM109, and arsA mutations in the pAD 
vector were sequenced with the pACT2 sequencing primers GAL4A3 (ACT TGC 
GGG GTT TTT CAG) and GAL4Act (TAC CAC TAC AAT GGA TG). 
Protein expression and purification 
Cells bearing the indicated plasmids were grown in LB medium overnight at 37°C 
and then diluted 50-fold into 1 L of the same medium.  Proteins were expressed 
by induction with 0.3 mM isopropyl-ß-D-thiogalactopyranoside at A600 of 0.6-0.8 
for 3 hrs.  Cells were harvested by centrifugation and washed once with a buffer 
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containing 50 mM MOPS, pH 7.5, 0.5 M NaCl, 5 mM DTT and 10 mM 2-
mercaptoethanol (Buffer A).  The cells were suspended in 5 ml of Buffer A per 
gram of wet cells and lysed by a single passage through a French press at 
20,000 psi.  Diisopropyl fluorophosphate (DIFP) was added at 2.5 μl/g wet cells 
immediately following French press.  Unbroken cells and membranes were 
removed by centrifugation at 150,000 x g for 1 h at 4 oC.  The supernatant was 
loaded at a flow rate of 0.5 ml/min onto a 10-ml Ni2+-nitrilotriacetic acid column 
(Qiagen) preequilibrated with Buffer A.  The column was then washed with 200 
ml of Buffer A followed by elution with 100 ml of Buffer A in which the 
concentration of imidazole was increased to 200 mM.  ArsA-containing fractions 
were identified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE), pooled, concentrated by centrifugation using a 10-kDa-cutoff 
Amicon ultracentrifugal filter (Millipore), mixed with 10% glycerol, aliquoted and 
stored at -80 oC until used. The protein concentrations were determined from 
their absorption at 280 nm (Gill and von Hippel, 1989). 
ATPase activity assays 
ATPase activity was estimated using a coupled assay (Vogel and Steinhart, 
1976), as described previously (Hsu and Rosen, 1989).  The assay mixture 
contained in 200 μl: 50 mM MOPS-KOH, pH 7.5, 0.25 mM Na2EDTA, 5 mM ATP, 
1.25 mM phosphoenolpyruvate, 0.25 mM NADH, 2 units of pyruvate kinase 
(Sigma) and lactate dehydrogenase (Sigma), 0.3 µM ArsA, 3 µM ArsD, and 
increasing concentrations of sodium arsenite, all pre-warmed to 37 oC.  The 
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reaction was initiated by the addition of 2.5 mM MgCl2 and followed by 
monitoring the decrease in absorbance at 340 nm using a Synergy H4 Hybrid 
Multi-Mode Microplate Reader (BioTek, Winooski, VT).  The pathlength 
correction feature of the microplate reader was used to automatically normalize 
absorbance values to a 1 cm pathlength.  The linear steady state rates were 
used to calculate the specific activity.  Each assay was repeated at least three 
times with two separate batches of purified protein.  The data were analyzed 
using SigmaPlot 12.0. 
Measurement of metalloid binding 
The buffer used for purification of ArsA was exchanged with a buffer containing 
50 mM MOPS-KOH, pH 7.5, 0.25 mM EDTA using a Micro Bio-Spin P-6 gel 
column (Bio-Rad, Hercules, CA).  Purified ArsA (10 µM) was incubated at 4 °C 
with 2.5 mM MgCl2, 2 mM ATPγS, and 100 µM antimonite.  After 1 h, each 
sample was passed through a Micro Bio-Spin P-6 gel column equilibrated with 
the same buffer.  The concentration of protein in the flow-through was quantified 
from the absorption at 280 nm (Gill and von Hippel, 1989).  An aliquot of the flow-
through (50 µl) was diluted with 2% HNO3, and the quantity of metalloid was 
measured by inductively coupled plasma-mass spectrometry (ICP-MS) with a 
PerkinElmer ELAN DRC-e.  Antimony standard solutions in the range of 0-50 ppb 
in 2% HNO3 were obtained from Ultra Scientific (North Kingstown, RI).  From 
these data the molar ratio of Sb(III) to protein was calculated. 
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Model building and docking analysis 
The model for the open form of ArsA was generated as described earlier (Ye et 
al., 2010).  ArsD was modeled based on its crystal structure (PDB ID: 3MWH), 
and its missing active site loop (residues 10 to 19) was built using the 
MODELLER program (Sali and Blundell, 1993).  The ArsA and ArsD models 
were energy minimized individually before being docked by the NAMD/VMD 
program (Humphrey et al., 1996; Phillips et al., 2005).  Docking was done by the 
online server HexServer (http://hexserver.loria.fr) (Macindoe et al., 2010).  
Hydrogen bonds and interactions (∆Gdiss values) were calculated by the 
PDBePISA server (http://www.ebi.ac.uk/pdbe/prot_int/pistart.html) (Krissinel and 
Henrick, 2007).  Domain rotation was performed using Chimera 
(http://www.cgl.ucsf.edu/chimera) (Pettersen et al., 2004).  Structural models 
were rendered using PyMOL (http:// www.pymol.org) (DeLano, 2001). 
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Results 
ArsA ATPase mutants exhibiting stronger interaction with ArsD 
The interaction of ArsA ATPase and ArsD metallochaperone has been 
demonstrated earlier (Lin et al., 2006) using the yeast two-hybrid analysis (Fields 
and Song, 1989).  The arsD gene was cloned into the C-terminal DNA-binding 
domain (BD) as bait, and the arsA gene was cloned into the C-terminal activation 
domain (AD) as prey of the split GAL4 transcriptional activator.  Interaction of the 
two proteins resulted in expression of the HIS3 reporter gene, allowing growth of 
yeast cells on media lacking histidine (Lin et al., 2006) (Figure 9).  The yeast two-
hybrid showed that the quadruple ArsD mutant K2A/K37A/K62A/K104A (4KA 
ArsD) does not interact with wild type ArsA (Yang et al., 2011) (Figure 9).  In the 
present study, random mutagenesis of arsA was performed by ep-PCR induced 
with Mn2+ (Cadwell and Joyce, 1992) using a pair of primers homologous to the 
flanking regions of the arsA gene in plasmid pAD-WT ArsA, in which arsA was 
fused to the sequence for the GAL4 DNA-activation domain.  The purified ep-
PCR product was mixed with plasmid pAD-ArsA linearized with BamHI and 
EcoRI, co-transformed with pBD-4KA ArsD into Saccharomyces cerevisiae strain 
AH109 and selected on SD (-His/-Leu/-Trp) plates.  By this method the ep-PCR 
fragments integrate into pAD-ArsA in vivo through homologous recombination 
(Hua et al., 1997).  Twenty-two colonies were isolated on SD (-His/-Leu/-Trp) 
plates that showed interaction with 4KA ArsD.  The arsA gene from each colony 
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was sequenced.  Of the 22 colonies, some were duplicates, and 15 were unique 
(Table 3).  Of those 15, only one clone contained a single mutation (D137V),  
while the other clones contained multiple mutations in the arsA gene.  Some 
substitutions such as Q56R, T115K, F120L and K404R were found in more than 
one mutant.  Conservative substitutions were found at residue 120; Phe120 
altered to either Ile or Leu.  Using a combination of X-ray crystallography and in 
silico modeling and docking studies, 20 residues of ArsA were predicted to be 
within 4 Å of 30 ArsD residues, and they may form the contact regions between 
the two proteins (Ye et al., 2010).  On the basis of the in silico predictions (Ye et 
al., 2010) and also because some of the mutations occurred more than once, 
1 1:
10
1:
10
0
1:
10
00
1 1:
10
1:
10
0
1:
10
00
1 1:
10
1:
10
0
1:
10
00
1 1:
10
1:
10
0
1:
10
00
1 1:
10
1:
10
0
1:
10
00
1 1:
10
1:
10
0
1:
10
00
pBD-4KA ArsD
pAD-WT ArsA
pAD-D137V ArsA
pAD-F120I ArsA
pAD-Q56R ArsA
pAD-WT ArsA
pAD-D137V ArsA
pAD-F120I ArsA
pAD-Q56R ArsA
SD (-Leu/-Trp) SD (-His/-Leu/-Trp)
+ 10 mM 3-AT + 30 mM 3-AT + 60 mM 3-AT + 90 mM 3-AT- 3-AT
pBD-ArsD
Figure 9.  Yeast two-hybrid analysis of ArsA mutants exhibiting increased interaction 
with ArsD.  S. cerevisiae strain AH109 bearing pAD-A (wild-type ArsA) or pAD-AX (single 
ArsA mutants Q56R, F120I or D137V) and either pBD-ArsD or pBD-4KA ArsD plasmids 
was grown in SD medium overnight and inoculated with 10-fold serial dilutions on SD agar 
plates lacking leucine, tryptophan or histidine and supplemented with the indicated 
concentrations of 3-AT. The plates were incubated at 30 °C for 3 days and scored for 
growth. 
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seven mutations (Q56R, V90F, T115K, F120I, V190I, K404R, and E506G) were 
reintroduced individually by site-directed mutagenesis into the arsA gene to  
  
Table 3.  ArsA mutants exhibiting interaction with 4KA ArsD 
ArsA mutations Times isolated 
E34K/ G51C/ S55T/ R88I/ V90F/ V101L 1 
E34K/ G51C/ R88I/ F120L/ K404R 1 
Q56R/ T115K/ Q182L/ S210T/ N229D/ A345G/ T497M 1 
Q56R/ T115K/ Q182L/ S210T/ N229D/ T497M 1 
L71S/ V190I 1 
V96A/ D121E 3 
F120L/ E168G/ M354V/ N374I/ S376I 1 
F120L/ L201P/ V435A/ S560R 1 
F120I/ K404R 1 
D137V 5 
F162I/ Q307R 2 
E168G/ M354V/ N374I/ K402M 1 
Q182R/ E258V/ T451S/ E506G 1 
Y188N/ Y305C/ E415G/ D447G 1 
Y188N/ E415G/ D447G 1 
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examine whether the single ArsA mutants could interact with 4KA ArsD.  Other 
multiple mutations in the arsA gene have not yet been analyzed.  From the 
results of yeast two-hybrid analysis, three single ArsA mutants (Q56R, F120I and 
D137V) exhibited interaction with 4KA ArsD (Figure 9).  These ArsA mutants also 
interacted with wild type ArsD (Figure 9).   
The repressed transactivator two-hybrid system has been used to select 
for mutants with increased affinity for a binding partner (Hirst et al., 2001; Joshi et 
al., 2007; Yang et al., 2011).  The HIS3 gene encodes imidazole glycerol-
phosphate dehydratase, catalyzing the sixth step in histidine biosynthesis.  
Histidine synthesis by this enzyme is competitively inhibited by 3-AT 
(Klopotowski and Wiater, 1965).  If 3-AT is added to the medium, yeast cells 
must express higher levels of His3p to grow in the absence of histidine.  AH109 
yeast cells co-transformed with pBD-k-4KA (ArsD mutant 
K2A/K37A/K62A/K104A inserted into GAL4 binding domain in plasmid pGBT9) 
and pAD-AX (each of the single ArsA mutants (Q56R, F120I and D137V) fused 
to the GAL4 activation domain sequence in plasmid pACT2) could not grow on 
SD plates containing 10 mM 3-AT but lacking histidine, leucine and tryptophan.  
In contrast, AH109 yeast cells co-transformed with pBD-k-D (wild type ArsD) and 
pAD-AX (single ArsA mutants Q56R, F120I and D137V) were able to grow in the 
presence of up to 90 mM 3-AT (Figure 9).  These results indicate that the single 
ArsA mutants have increased interaction with wild type ArsD but not with 4KA 
ArsD. 
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Analysis of altered ArsAs 
Under physiological conditions, ArsA is a part of a complex with the ArsB 
protein in the inner membrane of E. coli.  When expressed at high levels, ArsA is 
found predominantly as a soluble protein in the cytosol (Rosen et al., 1988b).  
Soluble ArsA has been purified and shown to be an As(III)-stimulated ATPase 
(Hsu and Rosen, 1989; Rosen et al., 1988b).  Each altered ArsA was soluble in 
the cytosol and purified to >95% homogeneity using nickel affinity 
chromatography (Green et al., 2012).  There was no difference between the wild 
type and altered proteins in mobility on sodium dodecyl sulfate - polyacrylamide 
gel electrophoresis, nor was abnormal degradation of the altered proteins 
observed (Figure 10), indicating that the altered proteins folded relatively 
normally. 
25 kDa
35 kDa
50 kDa
75 kDa
100 kDa
- + - + - + - + - +
pET28 WT Q56R F120I D137V
ArsA
Figure 10.  Expression of altered ArsAs.  BL21(DE3) cells bearing either vector plasmid, 
wild type or altered arsA genes were grown and induced in the presence or absence of 0.3 
mM IPTG.  Cell suspensions were boiled in SDS sample buffer and analyzed by SDS-PAGE 
on 10% acrylamide gel.  The position of migration of purified ArsA is indicated by an arrow. 
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ATPase activity of ArsA mutants 
The ATPase activity of ArsA is stimulated by As(III) (Hsu and Rosen, 1989; 
Rosen et al., 1988b).  In the absence of metalloid, the wild type showed a basal 
ATPase activity of 25 nanomoles of ATP hydrolyzed/min/mg of protein.  In the 
presence of As(III), the wild type ArsA showed a 5.5-fold stimulation of ATPase 
activity over its basal rate.  Addition of ArsD to the assay mix increases the 
affinity of ArsA for As(III), i.e. ,decreases the concentration of As(III) required for 
half-maximal stimulation of ArsA ATPase activity, thereby increasing its ATPase 
activity at even lower concentrations of As(III) (Lin et al., 2006).  When wild type 
ArsD was added to the ATPase assay, the apparent affinity of ArsA for As(III) 
increased 8.5-fold (Figure 11 and Table 4).  Addition of 4KA ArsD to the  
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Figure 11.  Activation of ArsA ATPase activity by ArsD.  ArsA ATPase activity was 
assayed at the indicated concentrations of sodium arsenite in the presence or absence of 
either wild type or 4KA ArsD, as described under “Materials and Methods.”  The basal 
ATPase activity was subtracted from the total activity.  The curves were fitted using 
SigmaPlot 12.0, with the error bars representing the standard error.  Left panel, Wild-type 
ArsA; Right panel, Q56R ArsA.  (), no ArsD; (), wild type ArsD; (), 4KA ArsD.   
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Table 4.  ArsA ATPase kinetics in the presence or absence of either wild type or 4KA ArsD 
ArsA ArsD1 Vmax (nmol of ATP 
hydrolyzed/min/mg of protein) 
As(III)  
[C]50% activation 
(μM) 
-As(III) +As(III) 
Wild type none 25 ± 5 137 ± 10 382 ± 48 
 Wild type 35 ± 2 117 ± 6 45 ± 7 
 4KA ArsD 35 ± 2 117 ± 10 231 ± 40 
Q56R none 32 ± 2 83 ± 4 205 ± 20 
 Wild type 40 ± 2 87 ± 4 23 ± 4 
 4KA ArsD 40 ± 2 75 ± 5 109 ± 16 
F120I none 75 ± 2 75 ± 2 - 
 Wild type 80 ± 2 80 ± 2 - 
 4KA ArsD 82 ± 3 82 ± 3 - 
D137V none 55 ± 2 55 ± 2 - 
 Wild type 57 ± 2 57 ± 2 - 
 4KA ArsD 59 ± 2 59 ± 2 - 
1ArsD was added in a 10-fold molar excess over ArsA 
 
assay decreased the half maximal concentration for As(III) by 1.6-fold.  Q56R 
ArsA showed a similar basal ATPase activity as the wild type, which was 
stimulated 2.8-fold in the presence of As(III).  Addition of either wild type or 4KA 
ArsD to the assay mix increased the affinity for As(III) by 9-fold and 2-fold, 
respectively.  These results indicate that, although 4KA ArsD does not stimulate 
ArsA ATPase activity to the same degree as the wild type, it has a small but 
significant effect on the affinity of ArsA for As(III). 
 48 
 
The F120I and D137V ArsA showed a basal ATPase rate of 80 and 60 
nanomoles of ATP hydrolyzed/min/mg of protein, respectively.  The ATPase 
activity of either proteins were not stimulated by As(III); nor were any changes 
observed upon addition of either wild type or 4KA ArsD.  Note that both F120I 
and D137V ArsA show a basal ATPase rate that is similar to the As(III)-
stimulated rate of Q56R ArsA.     
Binding of Sb(III) to altered ArsAs 
To directly examine the binding of metalloid to ArsA, Sb(III) was used 
because it is bound with higher affinity than As(III) (Ruan et al., 2006).  ArsA has 
a single high affinity metalloid binding domain (Bhattacharjee et al., 1995; 
Bhattacharjee and Rosen, 1996; Ruan et al., 2006, 2008).  Each Sb atom is 
bound three-coordinately with Cys113, Cys172, and Cys422.  Binding of Sb(III) 
to altered ArsAs was measured by rapid gel filtration.  In the presence of 
saturating Mg2+ and the nonhydrolyzable nucleotide ATPγS, a stoichiometry of 
one mole of Sb(III) per mole of protein was observed for both wild type and Q56R 
ArsA, whereas a stoichiometry of 0.8 mole of Sb(III) per mole of protein was 
observed for F120I and D137V ArsA (Figure 12).  We do not consider this 
difference in Sb(III) binding as significant.  Overall, these results indicate that 
while F120I and D137V ArsA do not show metalloid-stimulated ATPase activity, 
their affinity for metalloid is unaffected by the mutations. 
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Docking analysis of the interaction between Q56R ArsA and ArsD  
ArsA undergoes a number of conformational transitions during the 
catalytic cycle, an open form in the absence of ATP and As(III), and a closed 
form when both are present (Ruan et al., 2008; Zhou and Rosen, 1997).  The X-
ray crystal structure of ArsA has been solved in the closed form with different 
nucleotides and metalloid (Zhou et al., 2000, 2001).  However, since metalloid 
transfer requires ArsA to be undergoing catalysis (Yang et al., 2010), it is likely 
that ArsD interacts initially with an open form of ArsA.  A S. cerevisiae 
BSA WT Q56R F120I D137V
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Figure 12.  ArsA mutants bind antimonite.  The antimony binding ability of wild-type and 
altered ArsA was assayed as described under “Materials and Methods.”  After incubation of 10 
μM ArsA and 100 μM potassium antimonyl tartrate at 4 °C in the presence of ATPγS and 
Mg2+, free Sb(III) was removed by gel filtration, and the Sb(III):ArsA molar ratio determined.  
Bovine serum albumin (BSA) was used as a negative control.  The error bars represent the 
standard deviation from three assays.   
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homologue of ArsA, Arr4p or Get3 (Auld et al., 2006; Shen et al., 2003) is 
involved in targeting tail-anchored proteins in the endoplasmic reticulum (Denic 
et al., 2013).  The crystal structures of Get3 from different yeast strains were 
solved in the open (nucleotide free) and closed (ADP-AlF4-) conformations 
(Bozkurt et al., 2009; Mateja et al., 2009).  An open model of the Q56R ArsA 
based on the open Get3 structure was generated, as described earlier (Ye et al., 
2010).  A model of the metalated form of ArsD was constructed on the basis of its 
crystal structure (PDB ID: 3MWH) with the missing active site loop (residues 10-
19) built using MODELLER (Sali and Blundell, 1993) and subjected to energy 
minimization using VMD/NAMD program (Humphrey et al., 1996; Phillips et al., 
2005).  The ArsA and ArsD structures were docked by the online protein docking 
server, HexServer (http://hexserver.loria.fr/), which produced a ranked list of 100 
docking predictions.  Since biochemical analysis indicates that the three 
cysteines of ArsD and the three cysteines of ArsA must be in proximity for 
transfer (Lin et al., 2007a), and also that Q56R ArsA interacts strongly with wild 
type ArsD, the single model most consistent with these parameters was selected 
(Figure 13A).  The docking analysis predicts 40 Q56R ArsA residues are within 4 
Å of 39 residues of wild type ArsD (Table 5).  Many of these ArsA residues are 
positively charged (e.g. Arg56, Arg86 and Arg556) or negatively charged (e.g., 
Glu75, Asp77, Glu515 and Glu552).  These residues are close enough to form 
charge pairs with residues in ArsD.  For example, ArsA residues Glu75 and 
Arg86 are close enough to ArsD residues Lys37 and Asp21, respectively, to form 
three salt bridges.  Similarly, the in silico modeling of Q56R ArsA and 4KA ArsD 
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complex predicts 13-hydrogen bonds and 2-salt bridges between ArsA and ArsD.  
Our results are consistent with an arginine substitution at ArsA residue 56 
altering the interaction with ArsD by changes in hydrogen bonding and salt 
bridges that propagate to the interface between the two proteins. 
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A
R56
D137
B
R56
D137
F120
F120
Figure 13.  In silico docking analysis of ArsA-ArsD complex. (A)  Cartoon diagram of the 
interaction between Q56R ArsA and wild type ArsD.  ArsD attaches to the back of ArsA with the 
cysteine rich loop (Cys12, Cys13, and Cys18) of ArsD (cyan) hanging down the metalloid binding 
domain of the open form of ArsA (ArsA1 in orange and ArsA2 in split pea).  R56, F120 and D137 in 
ArsA are represented by magenta ball and sticks.  The active site thiolates in both ArsA and ArsD 
are represented by yellow ball and sticks.  (B) Cartoon diagram of the interaction of Q56R ArsA and 
wild type ArsD based on an earlier model (Ye et al., 2010).  ArsD (cyan) is proposed to fit into the 
cavity of the open form of ArsA (ArsA1 in orange and ArsA2 in split pea).   
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Table 5.  Q56R ArsA and wild-type ArsD residues predicted from in silico docking to be 
within 4 Å of each other 
Q56R ArsA residues Wild-type ArsD residues 
Pro46 Arg45, Gln51 
Ala47 Phe46 
Ser48 Glu44 
Gly51 Gln42 
Gln52 Met5 
Ser55 Gln42 
Arg56 Gln38, Cys39, Gly40, Gln42 
Thr57 Gly40, Val41, Gln42, Glu44 
Ile58 Lys37, Gln38 
Gly59 Gln34 
Asn60 Gln34, Gln38 
Thr61 Gln38 
Gln63 Gln38 
Glu75 Lys37, Glu44 
Asp77 Gln34 
Gln79 Arg45, Asn47, Gln51 
Ala80 Gln34 
Gln83 Ser30, Arg45 
Gln84 Ser30, Thr31 
Arg86 Asp21, Val22 
Ser103 Asp21 
Asn106 Asp21 
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Glu107 Thr20, Asp21, Val22 
Asn281 Gln57 
Met282 Gln57 
Thr501 Pro52, Met53 
Leu505 Cys13 
Ala508 Ser14, Thr15 
Asn509 Cys13, Ser14 
Gln511 Thr15 
Ala512 Thr15, Gly16 
Glu515 Gly16 
Gln545 Glu59, Lys62 
Gln546 Val56, Gln57 
Pro549 Phe55, Val56, Lys62 
Gln550 Pro52, Val56 
Glu552 Ile65, Glu66 
Arg556 Ile65, Glu66, Ala67, Ser68, Gly69, Ala70, Glu71 
Gln557 Pro9, Ala10, Ala70, Glu71 
His558 Thr15 
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Discussion 
The ArsD metallochaperone delivers As(III) to ArsA ATPase, the catalytic 
subunit of ArsAB pump.  Interaction with ArsD increases the affinity of ArsA for 
As(III), conferring resistance to environmental concentrations of arsenic (Lin et 
al., 2006).  Genetic, biochemical and crystallographic data indicate that ArsD 
residues Cys12, Cys13, and Cys18 are involved in the transfer of As(III) to ArsA 
(Lin et al., 2007a; Yang et al., 2010; Ye et al., 2010).  ArsA has two homologous 
halves, ArsA1 and ArsA2, each with a nucleotide binding domain, NBD1 (residue 
1-296) and NBD2 (residue 305-583) connected by a short linker (Zhou et al., 
2000).  Two cysteine residues from NBD1 (Cys113 and Cys172) and a single 
cysteine (Cys422) from NBD2, form a high-affinity metalloid binding site 
(Bhattacharjee and Rosen, 1996; Ruan et al., 2008).  ArsA undergoes a number 
of conformational transitions during the catalytic cycle, an open form in the 
absence of ATP and As(III), and a closed form when both are present (Ruan et 
al., 2008; Zhou et al., 2000, 2001; Zhou and Rosen, 1997).  Biochemical analysis 
suggests that the three cysteines of ArsD must be in proximity to the three 
cysteines of ArsA for metalloid transfer (Lin et al., 2007a).  However, since 
metalloid transfer requires ArsA to be undergoing catalysis (Yang et al., 2010), it 
is likely that ArsD initially interacts with an open form of ArsA. 
 ArsD mutant K2A/K37A/K62A/K104A (4KA ArsD) does not interact with 
wild type ArsA in a two-hybrid assay (Yang et al., 2011).  Three suppressor 
mutations in ArsA (Q56R, F120I, and D137V) were isolated that exhibits 
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increased interaction with wild type ArsD than 4KA ArsD (Figure 9).  Each of 
these three residues in ArsA (Gln56, Phe120, and Asp137) is located in NBD1.  
Gln56 is situated in between the H3-S3 loop and exposed to solvent.  Phe120 is 
in the middle of H6 helix and surrounded by hydrophobic residues.  Asp137 is in 
the H7-S5 loop and exposed to solvent. 
A combination of in silico modeling and docking was used earlier to 
examine the interaction of ArsD metallochaperone with ArsA ATPase (Ye et al., 
2010).  The model depicted ArsD to fit into the cavity of the open form of ArsA 
(Fig. 13B).  This model predicted that ArsA residues His148, Arg151, Gly157, 
Ala158, Ser160, Ser161, Glu168, Ala170, Tyr394, Thr401, Lys402, Lys404, 
Glu405, Asp417, His453, Leu457, Leu458, Ala460, Thr461, and Arg516 are 
within 4 Å of the ArsD interface (Ye et al., 2010).  However, our two-hybrid 
screening for suppressor mutants with increased ArsA-ArsD interaction did not 
pick up any of the ArsA residues indicated above, except Lys404 (Table 3).  
Interestingly, the single ArsA mutant K404R did not interact with either the wild 
type or 4KA ArsD (data not shown).  This model also cannot explain the 
increased interaction of Q56R ArsA with ArsD.  As shown in Fig. 13B, Gln56 or 
its replacement is exposed to solvent and distant from the ArsA-ArsD interface. 
We now propose an alternate model for ArsA-ArsD interaction (Fig. 13A).  
While in the previous model, ArsD goes in a ‘frontal-attack’ mode with the open 
form of ArsA (Fig. 13B), in the new model, ArsD interacts such that its cysteine 
(Cys12, Cys13, and Cys 18) bearing loop is lowered into the active site of ArsA 
from its top (Fig 13A).  In this model, wild type ArsA-ArsD complex shows 16-
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intermolecular hydrogen bonds and 4-salt bridges, with a ∆Gdiss of 11.1 kcal/mol.  
The Q56R ArsA-wild type ArsD complex exhibits 28-intermolecular hydrogen 
bonds and 3-salt bridges, with a ∆Gdiss of 16.0 kcal/mol.  Thus, the alteration of 
Gln56 to arginine builds increased interaction with wild type ArsD, which supports 
the two-hybrid data.  The Q56R ArsA-4KA ArsD complex shows 13-
intermolecular hydrogen bonds and 2-salt bridges, and a ∆Gdiss of 7.8 kcal/mol.  
The alteration of four lysine residues in ArsD attenuates the positive charge, 
which in turn rearranges the surface charge on the protein surface and affects its 
interaction with ArsA.  However, if we determine the free energy of assembly 
dissociation using the earlier model (Ye et al., 2010) (Fig. 13B), the ∆Gdiss values 
for wild type ArsA and ArsD, Q56R ArsA-wild type ArsD, and Q56R ArsA-4KA 
ArsD complex are 15.4, 15.4, and 14.9 kcal/mol, respectively, predicting no 
differences in interaction between the altered ArsA and ArsD.  Thus, the new in-
silico model (Fig. 13A) supports our experimental data of Q56R ArsA strongly 
interacting with wild-type ArsD and weakly with 4KA ArsD.  The new model also 
accommodates most of the ArsD residues that were shown to interact with ArsA 
by two-hybrid analysis (Yang et al., 2011).  A side-by-side analysis comparing 
the two hybrid data (Table 2) and in silico docking predictions (Table 5) suggests 
that ArsA residues Gly51, Ser55, Arg88, Val90, Val101 and Ser560 might play a 
role in protein-protein interaction.  However, the effect of any of this single-
residue alteration on ArsA-ArsD interaction was not examined.      
It should be noted that the new model (Fig. 13A) predicts that the sulfur 
atoms of ArsA residues Cys113 and Cys172 are approximately 12 Å distant from 
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Cys12 and Cys13 of ArsD.  It is reasonable to assume that the complex 
undergoes multiple conformational changes that bring those residues in proximity 
to each other during other steps in the catalytic cycle. 
Neither model explains the increased interaction between F120I or D137V 
ArsA with the wild type or 4KA ArsD.  Both proteins show a basal ATPase activity 
that is not stimulated by As(III).  Both proteins bound Sb(III), albeit at a slightly 
lower stoichiometry than either the wild type or Q56R ArsA.  This suggests that 
neither the nucleotide nor metalloid binding site of F120I and D137V ArsA are 
affected by the mutation.  However, both showed a higher basal rate that is 
similar as the activated rate for Q56R ArsA.  We interpret this observation as the 
conformation of F120I and D137V are permanently locked in the metalloid bound 
form of the protein.  Why do these mutants interact strongly with ArsD?  An 
Asp137 to Val substitution is a major alteration of charge on the protein surface 
and probably creates a ‘sticky’ surface.  We predict that a Phe120 to Ile change 
affects the surface hydrophobicity of the protein that result in increased 
hydrophobic interactions with either wild type or 4KA ArsD, forming abortive 
complexes.  Identification of suppressor mutants that exhibit stronger interaction 
with ArsD provides an opportunity to perform co-crystallization experiments that 
would lead to characterization of the interface at the atomic level.   
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CHAPTER III 
Biochemical and biophysical characterization of CrArsM, an As(III) S-
adenosylmethionine methyltransferase, from Chlamydomonas reinhardtii 
(Parts of this chapter have been reproduced with permission of the International 
Union of Crystallography from Packianathan et al., 2014) 
Introduction 
While there are many toxins present in the environment, none is as 
pervasive as arsenic.  In fact, the 2013 Environmental Protection Agency’s 
Comprehensive Environmental Response, Compensation and Liability Act 
(CERCLA) Priority List of Hazardous Substances rank arsenic first based on a 
combination of their frequency, toxicity, and potential for human exposure 
(http://www.atsdr.cdc.gov/spl/).  The widespread impact of arsenic toxicity can be 
attributed to the ubiquity of arsenic in the environment (Zhu et al., 2014).  Natural 
sources of arsenic include soil and our water and food supplies. Arsenic 
consumption from foods, such as meats, vegetable and fish, have been linked 
with skin, bladder and lung cancer (Oberoi et al., 2014).   
Genes for As(III) S-adenosylmethionine methyltransferases (As3MTs) are 
widespread in the genomes of bacteria, archaea, fungi, lower plants and animals, 
including humans.  In microbes, the ArsM (synonymous with As3MT) orthologs 
detoxify arsenic (Qin et al., 2009; Qin et al., 2006).  In contrast, the health effects 
of arsenic may be attributed to methylation of inorganic arsenic by the human 
ortholog, hAS3MT, which catalyzes the biotransformation of As(III), primarily in 
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liver, to methylated products that are more toxic and carcinogenic in humans 
(Thomas et al., 2007; Thomas et al., 2004). 
To date the pathway of methylation remains controversial (Cullen, 2005).  
One hypothesis proposed by Challenger (Challenger, 1947) is that the enzyme 
catalyzes a series of alternating oxidative methylations and reductions, using S-
adenosylmethionine as the methyl donor to generate the pentavalent products 
methylarsenate (MAs(V), dimethylarsenate (DMAs(V)) and a lesser amount of 
trimethylarsine oxide (TMAs(V)O).  The trivalent species MAs(III), DMAs(III) and 
TMAs(III) are intermediates but not products.  Most consistent with this 
hypothesis is that humans primarily excrete DMAs(V) and to a lesser extent 
MAs(V) (Engstrom et al., 2011; Vahter, 1999)}.  However, with careful handling, 
trivalent methylated arsenicals can be detected in urine (Ding et al., 2012; Le et 
al., 2000).  More recently, Hayakawa and coworkers (Hayakawa et al., 2005) 
proposed an alternate pathway in which the preferred substrates of the 
methyltransferase are the glutathione (GSH) conjugates As(GS)3 and MAs(GS)2, 
and the products are the trivalent conjugates MAs(GS)2 and DMAs(GS).  In this 
pathway there is no change in the oxidation state of arsenic, which remains 
trivalent throughout the catalytic cycle.  The conjugates dissociate to unstable 
MAs(III) and DMAs(III), which rapidly oxidize non-enzymatically in air to MAs(V) 
and DMAs(V), the primary observed urinary species (Drobna et al., 2013; Le et 
al., 2000). 
To differentiate between these two hypotheses, Marapakala et al analyzed 
the enzymatic properties of an orthologue of human As3MT, CmArsM, from an 
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environmental isolate of the thermoacidophilic eukaryotic red alga 
Cyanidioschyzon merolae (Marapakala et al., 2012; Qin et al., 2009).  Purified 
CmArsM (411 residues, including a histidine tag) exhibits a temperature optimum 
of 60-70 oC.  All As(III) SAM methyltransferases identified to date have four 
conserved cysteines, at positions 44, 72, 174, and 224 in CmArsM.  Substitution 
of any of the four with alanine led to loss of As(III) methylation.  However, the 
C44A and C72A enzymes retained the ability to methylate MAs(III).  This 
indicates that Cys44 and Cys72 is not required MAs(III) methylation 
((Marapakala et al., 2012) and unpublished observation).  CmArsM has a single 
tryptophan residue that was changed to tyrosine to produce a tryptophan-free 
derivative.  In this background, Tyr70 was changed to a tryptophan, producing 
the single-tryptophan derivative Y70W.  Purified Y70W reported binding of As(III) 
and MAs(III) with quenching of protein fluorescence.  As(GS)3 and MAs(GS)2 
bound substantially faster than the free metalloids, supporting the hypothesis that 
glutathionylated arsenicals are preferred substrates for the enzyme (Hayakawa 
et al., 2005).  In the Y70W background, each of the single cysteine mutants, 
exhibited fluorescence quenching with addition of As(III), suggesting that the 
mutants bind but do not methylate As(III).  Moreover, the data indicated that all 
four cysteines are involved in As(III) methylation, but that only Cys174 and 
Cys224 are required for the second step, methylation of MAs(III) to DMAs(III).  
The rate-limiting step was identified as the conversion of DMAs(III) to TMAs(III), 
and DMAs(III) accumulates as the principal product (Marapakala, 2012 #5680 
and unpublished observation). 
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The crystal structure of CmArsM reveals the relationship between the 
arsenic and SAM binding sites to a final resolution of ∼1.6 Å (Ajees et al., 2012).  
In this structure, As(III) is bound by Cys174 and Cys224, while Cys72 moves 
towards Cys174 and Cys224 when SAM is bound.  The first 49 residues 
including Cys44 are not visible in this structure.  As(III) binding causes little 
change in conformation, but binding of SAM reorients helix α4 and a loop 
(residues 49−80) towards the As(III) binding domain, positioning the methyl 
group for transfer to the metalloid.  There is no evidence of a reductase domain, 
suggesting that arsenic remains trivalent during the catalytic cycle.  While this 
structure identifies the arsenic and SAM binding domains, as well as other 
residues potentially involved in arsenic biomethylation, a number of questions 
remain unanswered.  For example, the structure and function of the N- and C-
terminal domains that is not visible in this structure, and the participation of GSH 
in the catalytic mechanism. 
A more complete understanding of the catalytic mechanism of this family 
of enzymes would be aided by additional crystal structures from other orthologs.  
Comparison of the structure of orthologs will illuminate which domains and 
residues may be functionally significant.  A multiple amino acid sequence 
alignment of CmArsM with lower and higher eukaryotic ArsM homologues shows 
several conserved features (Figure 14).  For example, Cys44, Cys72, Cys174, 
and Cys224 in CmArsM is conserved in the other species examined.  
CrArsM from the eukaryotic green alga Chlamydomonas reinhardtii 
(AFS88933) catalyzes arsenic methylation and volatilization, leading to arsenic 
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resistance (Chen et al., 2013).  The gene for CrArsM, a 379-residue enzyme 
(41.6 kDa), was synthesized and expressed in Escherichia coli.  In this study, I 
describe the purification, preliminary biochemical characterization, crystallization, 
X-ray data collection and preliminary crystallographic analysis of CrArsM. 
 
 
Cyanidioschyzon    1 -----------------------------MPCSCA--------------- 
Ostreococcus       1 MAS-------ATVTAAPARATRATRRRDSSRSSATSPRATSARTRARA-R 
Chlamydomonas      1 -------------------------------------------------- 
Chlorella          1 MLCRVSTGRQFSVAAQPAARP---------PMSCCPPQNGAVKLKPTPPA 
Zebrafish          1 -------------------------------------------------- 
Human              1 -------------------------------------------------- 
Rat                1 -------------------------------------------------- 
 
 
Cyanidioschyzon    7 ------S-----GCQKSKNGGSTPSIRDHVADYYGKTLQSSADLKTSACK 
Ostreococcus      43 ASSSSSGALDALLGATIIAPGGDASVRASVQKYYGETLSTSDDLKTSACC 
Chlamydomonas      1 --MVEPASIAELSRAEQL-GKDQDAVRATVKEYYGETLKTSNDLRTSACT 
Chlorella         42 AVAGPASGIQELLEAKQL-GDNQQGVLDSVKEYYGEVLTTSEDLKTSACC 
Zebrafish          1 -------------MADAARDRTVTSVYNDVKEYYGKTLKQKSDLKSNACV 
Human              1 --------------MAA---LRDAEIQKDVQTYYGQVLKRSADLQTNGCV 
Rat                1 --------------MAA---PRDAEIHKDVQNYYGNVLKTSADLQTNACV 
 
 
Cyanidioschyzon   46 LAA-AVPESHRKILADIADEVLEKFYGCGSTLPADGSLEGATVLDLGCGT 
Ostreococcus      93 TPSEQIPKAVREALREVPDEVKAKYYGCGSPTPI--GIDGLRVLDLGSGS 
Chlamydomonas     48 ACK-APPPAVRAALADVPTEVKEKFYGCGNPIPA--GIEGLRVLDLGCGS 
Chlorella         91 TAG-SPPPLVRDALKKVPDEVKAKYYGCGSPFPM--GIQGLRVLDLGSGS 
Zebrafish         38 PSAKPVSAYVRKVIAEIHPDVVAKYYGCGLVVPE--CLEGCRVLDLGCGS 
Human             34 TTARPVPKHIREALQNVHEEVALRYYGCGLVIPE--HLENCWILDLGSGS 
Rat               34 TPAKGVPEYIRKSLQNVHEEVISRYYGCGLVVPE--HLENCRILDLGSGS 
 
 
Cyanidioschyzon   95 GRDVYLASKLVGEHGKVIGVDMLDNQLEVARKYVE-YHAEKFFGSPSRSN 
Ostreococcus     141 GRDCYVAAKLVGENGSVLGVDMTDGQLEVARKYVDEYCTKTLG--YAKAN 
Chlamydomonas     95 GRDCYVAAKLVGEKGSVTGVDMTPAQLEVAISHADAYCRDKLG--YGKSN 
Chlorella        138 GRDCYVCSALVGEGGSVTGVDMTPAQLAVARKYADEYCTQTLG--YAQPN 
Zebrafish         86 GRDCYMLSQLVGEKGHVTGIDMTEAQLEVARNYID-YHMQRFG--YKNPN 
Human             82 GRDCYVLSQLVGEKGHVTGIDMTKGQVEVAEKYLD-YHMEKYG--FQASN 
Rat               82 GRDCYVLSQLVGQKGHITGIDMTKVQVEVAKAYLE-YHTEKFG--FQTPN 
 
 
Cyanidioschyzon  144 VRFLKGFIENLATAEPEGVPDSSVDIVISNCVCNLSTNKLALFKEIHRVL 
Ostreococcus     189 MRFEKGTIEDLKA---AGVPDASVDMIISNCVINLSPDKPAVLSEAYRVL 
Chlamydomonas    143 MTFIQGEIEYLDR---AGLEDSSFDLVISNCVINLSPDKARVLSECYRVL 
Chlorella        186 MRFVEGEIEYLDK---AGIPDSSVDLIISNCVINLSPDKARVLREVYRVL 
Zebrafish        133 VNFVQGYIEALVE---AGLEDKSYDIIISNCVVNLSPDKSSVLREAYCVL 
Human            129 VTFIHGYIEKLGE---AGIKNESHDIVVSNCVINLVPDKQQVLQEAYRVL 
Rat              129 VTFLHGQIEMLAE---AGIQKESYDIVISNCVINLVPDKQKVLREVYQVL 
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Cyanidioschyzon  194 RDGGELYFSDVYADRRLSEAAQQDPILYGECLGGALYLEDFRRLVAEAGF 
Ostreococcus     236 ANGGEFYFSDVYCDRRLQEDLRSHEILLGECLGGAMYVEDFKRLCQAVGF 
Chlamydomonas    190 APGGEMHFSDVYVDRRLPQSVRSHPVLLGECLAGALYNNDFIRLSRKVGF 
Chlorella        233 APGGEMYFSDVYCDRRLPAEVRTHPVLLGECLGGALYTQDFLRLCRQVGF 
Zebrafish        180 KDGGELYFSDVYSDARIPEHLKANKTLWGECLSGALWWEDLIRLAEEVGF 
Human            176 KHGGELYFSDVYTSLELPEEIRTHKVLWGECLGGALYWKELAVLAQKIGF 
Rat              176 KYGGELYFSDVYASLEVSEDIKSHKVLWGECLGGALYWKDLAVIAKKIGF 
 
 
 
Cyanidioschyzon  244 RDVRLVSVGPVDVSDPQLRKLVPDVQFYSCTFRCFKVA--TLEATREDYG 
Ostreococcus     286 TDPRVLAGHEIEVRDPALAELLGEAKFYSITYRLFKLPPGCLETLCEDYG 
Chlamydomonas    240 TDPRQLECEEIQIHDAELRDQVGEARFYSITYRLFKVP-GQIEDLCEDYG 
Chlorella        283 LDPRTLSSAEIEVRDRELRELLGDARFFSITYRLFKLP-EAIETLCEDYG 
Zebrafish        230 CKPRLVSASIITVGNTELESILGDYKFVSATYRLFKLQKGLEKKPCL--- 
Human            226 CPPRLVTANLITIQNKELERVIGDCRFVSATFRLFKHSKTGPTKRCQ--- 
Rat              226 CPPRLVTANIITVGNKELERVLGDCRFVSATFRLFKLPKTEPAGRCQ--- 
 
 
Cyanidioschyzon  292 QSATYLGGIG---EEFKLDRFFTFPKEKPVRVDRNTAEIIRHSRLHQWFS 
Ostreococcus     336 QYAVYNGGLPGAPNAYQLDDHHRFEKNKPMLVCGNTGSMVGETWLGKYFT 
Chlamydomonas    289 QVAVYKGTIPGHSHAYDLDDHHRFVTNKPMLVCGNTASMVGESWLAPHFT 
Chlorella        332 QACKYKGTIPGAPHSYALDDHHTFQTGKWYEVCGNTAAMVGDSWMGKHFE 
Zebrafish        277 --VMYNGDITDSEESFEFDAQYAFKVDKVMEVDGDVANILRNSRFSEEFT 
Human            273 --VIYNGGITGHEKELMFDANFTFKEGEIVEVDEETAAILKNSRFAQDFL 
Rat              273 --VVYNGGIMGHEKELIFDANFTFKEGEAVEVDEETAAILRNSRFAHDFL 
 
 
Cyanidioschyzon  339 VSAEQ-QHMGLFKANDS--YALLHAPLSMQVEQLVCEVKKGSTDTCSEQA 
Ostreococcus     386 LVGDRSTHYGLFDCGPSPVAA-----------------S--------SSA 
Chlamydomonas    339 IIGDRAVHYGQFDCSGPKTTT-----------------GGAASPSNSAGA 
Chlorella        382 VVGDRSTHYGLFACGPAPA----------------------------AAP 
Zebrafish        325 FQPQGVNTASSGGCWAKPN-AVSVNPFEL---------VQQ---LGSASV 
Human            321 IRPIGEKLPTSGGCSALELKDIITDPFKL---------AEESDSMKSRCV 
Rat              321 FTPVEASLL------APQTKVIIRDPFKL---------AEESDKMKPRCA 
 
 
Cyanidioschyzon 386 SANGASCCATGRRCC- 
Ostreococcus 411 APAGGACC-------- 
Chlamydomonas 372 CGPGGACC-------- 
Chlorella  404 APAGGACC-------- 
Zebrafish         362 SPSTGGCCAGQESCCN 
Human   362 PDAAGGCCGTKKSC-- 
Rat   356 PEGTGGCCGKRKSC-- 
 
 
 
Figure 14. Multiple alignment of ArsM orthologs. Cyanidioschyzon merolae ArsM (FJ476310) 
was aligned with orthologs from Ostreococcus lucimarinus (XP_001421969), Chlamydomonas 
reinhardtii (AFS88933), Chlorella variabilis (XP_005845903), Zebrafish (NP_001034928), Rat 
(NP_543166) and human (AAI19639).  The black shading indicates identical amino acids; the 
grey shading indicates similar amino acids.  
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Materials and methods  
Reagents   
All chemicals were obtained from Sigma-Aldrich (St Louis, Missouri) 
unless otherwise mentioned. 
Cloning, expression and purification of CrArsM  
A CrArsM gene was designed based on the native gene with NcoI and 
XhoI restriction sites flanking 5’ and 3’ ends of the gene, respectively.  The 
synthetic version of CrArsM retained the conserved cysteine residues at 
positions 46, 74, 170 and 220, while all other cysteine residues were changed to 
alanine.  Trp332 and Tyr72 of native CrArsM protein were mutated to tyrosine 
and tryptophan residues, respectively.  The gene was chemically synthesized by 
Genscript USA Inc. (NJ) and inserted into vector plasmid pUC57 (Thermo Fisher 
Scientific, Waltham, MA).  The gene was subsequently cloned into vector 
plasmid pET29b(+) (EMD Biosciences, CA, USA) as a NcoI/XhoI digest, 
generating plasmid pET29-CrArsM in which the CrArsM gene is under control of 
T7 promoter and expressed with a six histidine tag at the C-terminus. 
Cells of BL21(DE3) pET29-CrArsM were grown at 37 oC in  Luria-Bertani 
medium (Green et al., 2012) containing 50 μg/ml of kanamycin with shaking at 
240 rev min-1.  When the absorbance at 600 nm of the culture reached 0.6, 0.1 
mM IPTG was added to induce expression of CrArsM.  The cells were grown for 
another 4 h, harvested by centrifugation (3,500 x g) for 30 min, washed once with 
buffer A (50 mM MOPS, pH 7.5, 0.5  M NaCl, containing 20% (w/v) glycerol, 20 
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mM imidazole and 10 mM 2-mercaptoethanol), and suspended in 5 ml of buffer A 
per g of wet cells.  The cells were lysed by two passes through a French 
pressure cell press at 20,000 psi and immediately treated with 2.5 μl/g wet cells 
of the protease inhibitor diisopropyl fluorophosphate.  Membranes and unbroken 
cells were removed by centrifugation at 150,000 x g for 1 h (Qin et al., 2006), and 
the supernatant solution at a flow rate of 0.5 ml/min was loaded on a 5 ml His-
trap HP column (GE Healthcare) pre-equilibrated with buffer A using an AKTA-
FPLC purification system (GE Healthcare).  The column was washed with 5 
column volumes of buffer A, followed by elution with 5 column volumes of buffer 
A containing 0.2 M imidazole.  Purified synthetic CrArsM was identified by SDS 
PAGE.  The migration of the band corresponded to the mass of CrArsM.  
Fractions containing CrArsM were concentrated by centrifugation using a 10-kDa 
cutoff Amicon Ultrafilter (EMD Millipore Corporation, Billerica, Massachusetts, 
USA) and was buffer exchanged with buffer C consisting of 50 mM MOPS, pH 
7.5, containing 0.5 M NaCl, 5 mM dithiothreitol  (DTT), 2.5 mM EDTA and 10% 
(w/v) glycerol, for storage at -80 °C until use.  The yield from 1 L of cell culture 
was 23 mg of purified protein. 
Arsenic methylation 
Methylation of As(III) and MAs(III) was assayed both in cells of E. coli 
expressing CrArsM genes and by purified proteins.  Individual colonies of E. coli 
strain BL21(DE3) bearing the appropriate plasmids were inoculated into 2 ml of 
LB medium supplemented with the appropriate antibiotics and incubated at 37 °C 
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overnight.  Late exponential phase cells were diluted 200-fold into 2 ml of LB 
medium containing 50 µg/ml kanamycin, 0.3 mM IPTG and 20 µM sodium 
arsenite.  After 12 h at 37 °C, the cells were removed by centrifugation, and the 
supernatant solution was immediately passed through a 3-kDa cut-off Amicon 
Ultrafilter (Millipore, Billerica, MA).  The filtrate was speciated by high-pressure 
liquid chromatography (HPLC) (PerkinElmer Series 2000) using a C18 reversed-
phase column eluted with a mobile phase consisting of 3 mM malonic acid, 5 mM 
tetrabutylammonium hydroxide, and 5% (v/v) methanol (pH 5.9) with a flow rate 
of 1 ml/min, and arsenic content was determined by inductively coupled plasma 
mass spectroscopy (ICP-MS) using an ELAN DRC-e spectrometer (PerkinElmer, 
Waltham, MA).  
Methylation activity of purified CrArsMs was assayed at 30 °C in a buffer 
consisting of 50 mM MOPS, pH 7.5, containing 150 mM KCl.  The assay mix 
contained 1 mM tris(2-carboxyethyl)phosphine (TCEP), 0.5 mM SAM, 10 µM 
As(III) and 1 µM CrArsM.  The reaction was terminated by adding 15% (v/v) H2O2 
to oxidize all arsenic species.  Denatured protein was removed by centrifugation 
using a 3 kDa cut-off Amicon Ultrafilter.  The filtrate was speciated by HPLC-ICP-
MS.  
Fluorescence assays  
Fluorescence measurements were performed on a temperature-controlled 
QuantaMaster™ UV VIS QM-4 Steady State Spectrofluorometer (Photon 
Technology International, Birmingham, NJ) at 25 oC.  For steady state 
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measurements, both emission and excitation monochromator slits were set at 1 
nm.  Samples were excited at 295 nm to excite tryptophan, and emission was set 
at 336 nm for time-based data acquisition.  Spectra were corrected for 
background fluorescence and Raman scattering by subtracting buffer spectra.  
The buffer used was 50 mM MOPS, 150 mM KCl, pH 7.5.  For determination of 
relative binding of free metalloids, As(III) and MAs(III), and preformed GSH 
conjugates, fluorescence spectra were acquired at the indicated concentrations 
of arsenicals in presence and absence of GSH.  To obtain binding rates, time-
based fluorescence quenching data were fitted to a single exponential decay 
isotherm using Prism 6 (GraphPad Software Inc).  
Crystallization  
The purified CrArsM was buffer exchanged into a buffer consisting of 50 
mM MOPS, pH 7.0 containing 0.5 M NaCl and 5 mM DTT.  Initial crystallization 
trials were performed using Hampton Research (Aliso Viejo, California, USA), 
Emerald Biosciences Inc. (Bainbridge Island, Washington, USA), and Jena 
Biosciences GmbH (Jena, Germany) crystal screen conditions using a hanging 
drop vapor diffusion method.  
At 18 oC and 20 C, crystallization trials produced crystalline aggregates 
upon mixing 2.0 μl each of protein and reservoir (20% PEG 3350, 0.2 M calcium 
acetate, 0.1 M Tris-HCl, pH 7.0) solutions.  Reduction of the PEG concentration 
from 20% to 18% led to formation of needle-like crystals that were used for 
seeding experiments.  The needles were transferred from the hanging drop to 
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Eppendorf tubes containing seed beads (Hampton Research) and 0.1 ml of well 
solution.  Sample preparation for seeding was as described previously 
(Marapakala et al., 2010).  Diffraction-quality crystals were obtained at room 
temperature using LINBRO 24 well plates (HR3-110) from Hampton Research.  
The wells, sealed with a cover slip, held 0.5 μl of seed stock (1:100 ratio) in drops 
containing equal volumes of protein and reservoir solutions (10% PEG 8000, 2.0 
M NaCl).  The crystals from a single drop were washed several times in 50% 
glycerol and dissolved in water for analysis by SDS PAGE. 
Data collection and processing   
Crystals were transferred to a cryoprotectant solution (10% PEG 8000, 2.0 
M NaCl, 20% 2-methyl-2,4-pentanediol) and flash-cooled in liquid nitrogen for 
data collection.  Initial crystals were screened at the Advanced Light Source of 
the Berkeley Center for Structural Biology.  Subsequent data sets were collected 
at the Southeast Regional Collaborative Access Team (SER-CAT) facility at the 
Advanced Photon Source (APS), Argonne, IL.  Data were obtained from 360 
image frames with 1º rotation angle about φ using a MAR-300 CCD detector 
under standard cryogenic conditions (100 °K) at a synchrotron beam line 22-BM 
with a crystal to detector distance of 240 mm.  The data sets were indexed, 
integrated and scaled with the HKL-2000 suite (Otwinowski and Minor, 1997). 
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Results 
Chemical synthesis of CrArsM 
The native CrArsM gene (Accession number JX480492.2) was expressed 
and purified as described (Chen et al., 2013).  However, the purified protein 
proved refractory to crystallization.  Native CrArsM has 17 cysteine residues, of 
which four are conserved in orthologs (Figure 14).  Multiple cysteine residues in 
proteins often interfere with crystallization.  For that reason, the CrArsM gene 
was chemically synthesized.  In the synthetic version, the four conserved 
cysteine residues at positions 46, 74, 170 and 220 were retained, while the other 
13 cysteine residues were changed to alanine residues.  Also, in order to 
measure ligand binding by monitoring the changes in intrinsic tryptophan 
fluorescence, Trp332 and Tyr72 of native CrArsM protein were mutated to 
tyrosine and tryptophan residues, respectively (Figure 15).  The sequence of the 
gene was optimized using the OptimumGeneTM algorithm (Genscript) which 
improves expression by analyzing and upgrading the codon adaptation index 
(Sharp and Li, 1987), modifying GC content and disrupting stem-loop structures 
that affect ribosome binding and stability of the mRNA (Figure 16).  Otherwise 
the sequence of the synthetic protein was the same as native CrArsM (Figure 
15). 
 
 
 
 71 
 
 
 
 
Synthetic CrArsM  1 MVEPASIAELSRAEQLGKDQDAVRATVKEYYGETLKTSNDLRTSACTAAKAPPPAVRAAL
 Native CrArsM  1 MVEPASIAELSRAEQLGKDQDAVRATVKEYYGETLKTSNDLRTSACTACKAPPPAVRAAL
Synthetic CrArsM 61 ADVPTEVKEKFWGCGNPIPAGIEGLRVLDLGAGSGRDAYVAAKLVGEKGSVTGVDMTPAQ
Native CrArsM 61 ADVPTEVKEKFYGCGNPIPAGIEGLRVLDLGCGSGRDCYVAAKLVGEKGSVTGVDMTPAQ
Synthetic CrArsM 121LEVAISHADAYARDKLGYGKSNMTFIQGEIEYLDRAGLEDSSFDLVISNCVINLSPDKAR
Native CrArsM 121LEVAISHADAYCRDKLGYGKSNMTFIQGEIEYLDRAGLEDSSFDLVISNCVINLSPDKAR
Synthetic CrArsM 181VLSEAYRVLAPGGEMHFSDVYVDRRLPQSVRSHPVLLGECLAGALYNNDFIRLARKVGFT
Native CrArsM 181VLSECYRVLAPGGEMHFSDVYVDRRLPQSVRSHPVLLGECLAGALYNNDFIRLCRKVGFT
Synthetic CrArsM 241DPRQLEAEEIQIHDAELRDQVGEARFYSITYRLFKVPGQIEDLAEDYGQVAVYKGTIPGH
Native CrArsM 241DPRQLECEEIQIHDAELRDQVGEARFYSITYRLFKVPGQIEDLCEDYGQVAVYKGTIPGH
Synthetic CrArsM 301SHAYDLDDHHRFVTNKPMLVAGNTASMVGESYLAPHFTIIGDRAVHYGQFDASGPKTTTG
Native CrArsM 301SHAYDLDDHHRFVTNKPMLVCGNTASMVGESWLAPHFTIIGDRAVHYGQFDCSGPKTTTG
Synthetic CrArsM 361 GAASPSNSAGAAGPGGAAALEHHHHHH  
   Native CrArsM 361 GAASPSNSAGACGPGGACCLEHHHHHH 
Figure 15.  Comparison of sequence of native and synthetic CrArsM 
 72 
 
 
 
      M  V  E  P  A  S  I  A  E  L  S  R  A  E  Q  L  G  K  D  Q   
    1 ATGGTGGAACCGGCATCTATCGCTGAACTGTCCCGTGCTGAACAACTGGGCAAAGACCAA 60 
      D  A  V  R  A  T  V  K  E  Y  Y  G  E  T  L  K  T  S  N  D   
   61 GACGCTGTCCGTGCTACCGTGAAGGAATACTATGGTGAAACGCTGAAAACCAGCAACGAT 120 
      L  R  T  S  A  C  T  A  A  K  A  P  P  P  A  V  R  A  A  L    
  121 CTGCGCACGTCTGCTTGTACCGCCGCAAAGGCACCGCCGCCGGCCGTGCGTGCAGCTCTG 180 
      A  D  V  P  T  E  V  K  E  K  F  W  G  C  G  N  P  I  P  A 
  181 GCCGATGTGCCGACGGAAGTTAAAGAAAAGTTTTGGGGCTGTGGTAATCCGATTCCGGCG 240 
      G  I  E  G  L  R  V  L  D  L  G  A  G  S  G  R  D  A  Y  V  
  241 GGTATCGAAGGCCTGCGCGTTCTGGATCTGGGCGCTGGTAGTGGCCGTGACGCGTATGTC 300 
      A  A  K  L  V  G  E  K  G  S  V  T  G  V  D  M  T  P  A  Q 
  301 GCGGCCAAACTGGTGGGTGAAAAGGGCTCCGTTACGGGCGTCGATATGACCCCGGCTCAG 360 
      L  E  V  A  I  S  H  A  D  A  Y  A  R  D  K  L  G  Y  G  K 
  361 CTGGAAGTGGCGATTTCACATGCAGATGCTTATGCGCGCGACAAACTGGGTTACGGCAAG 420 
      S  N  M  T  F  I  Q  G  E  I  E  Y  L  D  R  A  G  L  E  D 
  421 TCGAACATGACCTTTATTCAAGGTGAAATCGAATACCTGGATCGTGCAGGCCTGGAAGAT 480 
      S  S  F  D  L  V  I  S  N  C  V  I  N  L  S  P  D  K  A  R 
  481 AGCTCTTTCGACCTGGTTATTAGTAACTGCGTCATCAATCTGTCCCCGGATAAAGCGCGT 540 
      V  L  S  E  A  Y  R  V  L  A  P  G  G  E  M  H  F  S  D  V 
  541 GTCCTGAGCGAAGCATATCGTGTGCTGGCACCGGGCGGTGAAATGCATTTTTCTGATGTG 600 
      Y  V  D  R  R  L  P  Q  S  V  R  S  H  P  V  L  L  G  E  C 
  601 TACGTTGACCGTCGCCTGCCGCAGAGTGTGCGTTCCCACCCGGTTCTGCTGGGTGAATGT 660 
      L  A  G  A  L  Y  N  N  D  F  I  R  L  A  R  K  V  G  F  T 
  661 CTGGCCGGCGCACTGTATAACAATGATTTTATTCGTCTGGCCCGCAAAGTGGGTTTCACC 720 
      D  P  R  Q  L  E  A  E  E  I  Q  I  H  D  A  E  L  R  D  Q 
  721 GACCCGCGTCAGCTGGAAGCTGAAGAAATTCAAATCCACGATGCGGAACTGCGTGACCAA 780 
      V  G  E  A  R  F  Y  S  I  T  Y  R  L  F  K  V  P  G  Q  I 
  781 GTGGGCGAAGCACGCTTTTATTCTATTACGTACCGTCTGTTCAAAGTTCCGGGTCAGATC 840 
      E  D  L  A  E  D  Y  G  Q  V  A  V  Y  K  G  T  I  P  G  H 
  841 GAAGATCTGGCCGAAGACTATGGCCAAGTCGCAGTGTACAAGGGTACCATCCCGGGCCAT 900 
      S  H  A  Y  D  L  D  D  H  H  R  F  V  T  N  K  P  M  L  V 
  901 AGCCACGCCTACGATCTGGATGACCATCACCGCTTCGTTACGAACAAACCGATGCTGGTC 960 
      A  G  N  T  A  S  M  V  G  E  S  Y  L  A  P  H  F  T  I  I 
  961 GCCGGTAATACCGCATCAATGGTCGGCGAATCGTATCTGGCGCCGCATTTTACCATTATC 1020
      G  D  R  A  V  H  Y  G  Q  F  D  A  S  G  P  K  T  T  T  G 
 1021 GGTGATCGTGCCGTTCACTACGGCCAGTTCGACGCAAGTGGCCCGAAAACCACGACCGGT 1080
      G  A  A  S  P  S  N  S  A  G  A  A  G  P  G  G  A  A  A  L 
 1081 GGTGCGGCAAGTCCGTCAAACTCAGCGGGTGCGGCGGGTCCGGGCGGTGCGGCGGCGCTC 1140
      E  H  H  H  H  H  H  * 
 1141 GAGCACCACCACCACCACCACTGA 1164 
Figure 16.  Translation of optimized sequence of synthetic CrArsM 
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Catalytic properties of synthetic CrArsM  
Wild-type CrArsM and the synthetic variant, both with a 6 x His tag were 
expressed in E. coli and purified in a single step by Ni(II)-nitrilotriacetic acid 
(NTA) chromatography.  Both proteins were examined for their ability to 
methylate inorganic As(III).  While it is possible that the mutations may create 
structural alterations that could affect activity, synthetic CrArsM was produced in 
amounts comparable to that of the wild type and was soluble in the cytosol, 
indicating relatively normal folding. 
In the presence of TCEP and SAM, and after 1 h of incubation at 30 °C, 1 
µM of wild-type CrArsM was able to near completely methylate 10 µM As(III) to 
DMAs(III), which was converted to DMAs(V) upon treatment with H2O2 (Figure 
17).  Under similar conditions, the synthetic variant could convert ~50% As(III) to 
MAs(III) and DMAs(III), which are detected as MAs(V) and DMAs(V) after 
oxidation with H2O2.  The low activity of synthetic CrArsM may be on account of 
local conformational changes due to multiple alterations of cysteines to alanines. 
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Figure 17.  Methylation of As(III)  by wild-type and synthetic CrArsM 
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Tryptophan fluorescence spectroscopy 
Intrinsic tryptophan fluorescence has been extensively exploited in examining 
arsenic binding in arsenic detoxification proteins (Marapakala et al., 2012; Yang 
et al., 2010; Zhou and Rosen, 1997; Zhou et al., 2002).  CrArsM has a single 
tryptophan at position 332, but the fluorescence of the wild-type protein does not 
respond to ligand binding 
(data not shown).  A 
homology model of 
CrArsM built on the 
CmArsM native structure 
(PDB Id: 4FS8) using the 
SWISS-MODEL fully 
automated protein 
structure homology 
modeling server 
(http://swissmodel.expas
y.org/) (Kiefer et al., 
2009) (Figure 18) shows 
that, Tyr72 is located on a loop near Cys74, and may respond to metalloid 
binding at the active site cysteines.  Therefore, Trp332 was changed to a tyrosine 
residue and Tyr72 was replaced by a tryptophan in the synthetic CrArsM. 
Figure 18.  Homology modeling of CrArsM based on 
CmArsM native structure. 
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The polarity of microenvironment of tryptophan residues in a protein can 
be assessed from their fluorescence emission spectra (Lakowicz, 1983).  In a 
less polar environment the maximum emission wavelength (λmax) of tryptophan 
shifts to a lower wavelength, with an increase in the fluorescence yield 
(Lakowicz, 1983).  When excited at 295 nm, free tryptophan in an aqueous 
solution has a λmax at 356 nm (Figure 19), whereas the λmax of Trp72 (synthetic 
CrArsM) was 348 nm.  
Addition of either As(OH)3 
or As(GS)3 to CrArsM 
resulted in a blue shift with 
a λmax at 340 nm, which 
suggests that Trp72 is 
positioned in a more 
hydrophobic environment 
after the addition of 
metalloid.  There is also 
significant quenching of 
tryptophan fluorescence.  
Our interpretation is that 
the Trp72 is forming a 
stable complex with 
metalloid, thereby reducing 
320 340 360 380 400
0
10000
20000
30000
40000
50000
Fl
uo
re
sc
en
ce
 (a
rb
itr
ar
y 
un
its
)
Emission wavelength (nm)
Trp
CrArsM
CrArsM + As(GS)3
CrArsM + As(OH)3
Figure 19.  Emission spectra of synthetic CrArsM.  
Samples were excited at 295 nm and emission spectra 
were acquired at 23 oC as described in Materials and 
Methods.  The emission spectra of 1 μM CrArsM and 
upon addition of either 100 μM As(OH)3 or As(GS)3 were 
compared with that of 1 μM tryptophan. 
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the number of fluorophores that can emit.  Further experiments are needed to 
determine the quenching mechanism. 
The effect of arsenicals on the time course of fluorescence quenching of 
synthetic CrArsM was examined (Figure 20).  Addition of As(III) showed a 
gradual quenching of the fluorescence signal.  In contrast, the rate of quenching 
upon addition of As(GS)3 follows a biphasic curve with an extremely fast phase 
that is difficult to quantify by traditional methods.  Overall, the experiment shows 
that binding of glutathione conjugates is extremely rapid, but detailed rate 
determinations will require stopped-flow analysis. 
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Figure 20.  Effect of As(OH)3 and As(GS)3 on the fluorescence of synthetic CrArsM.  
Protein fluorescence was assayed at 23 oC with excitation and emission wavelengths of 
295 and 355 nm, respectively, as described in Materials and Methods.  Each assay 
contained 2 μM CrArsM.  Arrow indicates the addition of either As(OH)3 or As(GS)3. 
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Crystallization studies 
Needle crystals of CrArsM initially diffracted to a resolution range from 7.0 
Å to 4.5 Å, but improved with seeding.  Diffraction-quality crystals formed 
overnight with dimensions of 0.3 x 0.3 x 0.2 mm (Figure 21).   
 
 
 
 
 
 
 
 
 
Complete data sets were collected up to 2.40 Å resolution using a single 
crystal of CrArsM (Figure 22).  The data processing statistics are shown in Table 
6.  The crystals belonged to R3: H space group with unit cell parameters of  a = b 
= 157.8 Å and c = 95.4 Å; γ =120°.  Evaluation of crystal packing parameters 
indicated that the lattice can accommodate two molecules in the asymmetric unit 
with a Matthews’s coefficient of 2.73 Å3Da-1 and a solvent content of 54.9 %. 
 
Figure 21.  Crystals of CrArsM were grown by hanging drop vapor diffusion. 
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Figure 22.  The diffraction images (1° oscillation) were collected from 
CmArsM crystals at APL, Argonne National Laboratory, using a MAR 300 
detector at 100 °K.  The edge of the image corresponds to 2.40 Å resolution. 
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Table 6. Data collection and processing 
Diffraction source Synchrotron (APS 22-BM) 
Wavelength (Å) 1.00 
Temperature (K) 100 
Detector                                                    MAR-300 CCD detector 
Crystal-detector distance (mm)  240 
Rotation range per image (°)  1 
Total rotation range (°)  360 
Exposure time per image (s)  3.9 
Space group R3:H 
a, b, c (Å)  157.8, 157. 8, 95.4 
α, β, γ (°)  90.0, 90.0,120.0 
Mosaicity (°)   0.2 
Resolution range (Å) 50-2.40 (2.40-2.49) 
Total No. of reflections  404,464 (40,054) 
No. of unique reflections 34,690 (3483) 
Completeness (%) 100 (100) 
Redundancy 11.7 (11.5) 
<I/σ(I)> 34.1 (6.8)   
Rr.i.m.  8.3 (42.8)  
Rmerge 8.0 (40.9) 
Mattews coefficient (Å3Da-1) 2.73 
Overall B factor from Wilson plot (Å2)  45.2  
Note: Values for the outer shell are given in parentheses. 
Rmerge = hkli Ii (hkl)‐ (I(hkl))  hkl i Ii(hkl), where Ii(hkl) is the observed intensity and 
(I(hkl) is the average intensity over symmetry equivalent measurements. 
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Structure of CrArsM 
The structure of CrArsM has been determined to a final resolution of 2.4 Å 
(Packianathan et al, unpublished data).  Overall, the structure has three domains: 
N-terminal domain, SAM 
binding domain, and the 
C-terminal domain.  The 
structure shows residues 
50 through 372.  The first 
49 residues in the N-
terminal domain are not 
visible.  The three 
conserved cysteines, 
Cys74, Cys170 and 
Cys220 form the As(III) 
binding site.  Cys46, one 
of the four conserved 
cysteines, cannot be seen 
in this structure (Figure 
23).  The novelty of this 
structure is the 
observation of a disulfide 
bond between the 
conserved cysteines, Cys74 and Cys170.    
SAM binding domain
C-terminal domain
N-terminal
domain
Cys74 Cys170
Cys220
As(III) binding
site
As(III) binding
site
Figure 23.  Overall structure of CrArsM. Top, The 
secondary structure elements are drawn as cartoon 
diagram.  Bottom, Surface representation of CrArsM with the 
As(III) binding site shown in yellow
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Discussion 
Eukaryotic ArsMs have been refractory to crystallization.  This may be because 
ArsM have a number of cysteine residues, which give rise to undefined 
aggregates, thereby hindering the crystallization process.  A multiple sequence 
alignment of several eukaryotic ArsM homologs shows the presence of four 
conserved cysteines (Figure 14).  A synthetic variant of CrArsM was constructed 
that retained the four conserved cysteines at position 46, 74, 170 and 220 of the 
primary sequence.  The remaining 13 cysteines were altered to alanine.  
Synthetic CrArsM was able to convert As(III) to mono- and dimethyl derivatives, 
although at a reduced efficiency than the wild type enzyme.  Furthermore, 
synthetic CrArsM bound the glutathione conjugate of As(III) extremely rapidly.  
These preliminary experiments indicated that the synthetic version behaved 
similarly as the wild type.    Diffraction quality crystals of synthetic CrArsM formed 
overnight at room temperature.  The structure was resolved at 2.4 Å resolution.  
Cys74, Cys170 and Cys220 form the As(III) binding site.  This structure does not 
have any As(III) bound to its active site.  Cys74 and Cys170 form a disulfide 
bond.  This structure is different from that of CmArsM (PDB ID: 4FS8) where no 
disulfide bonds were found in the native structure. 
Human As(III) S-adenosylmethionine (SAM) methyltransferase (hAS3MT) 
has four conserved cysteines, Cys32, Cys61, Cys156, Cys206 (Figure 14).  A 
synthetic gene encoding hAs3MT was expressed, and the purified enzyme 
characterized (Dheeman et al 2014).  The synthetic enzyme is considerably more 
active than a cDNA-expressed enzyme using endogenous reductants thioredoxin 
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(Trx), thioredoxin reductase (TR), NADPH and reduced glutathione (GSH).  Each 
of the seven cysteines (the four conserved residues Cys32, Cys61, Cys156, 
Cys206, and non-conserved Cys72, Cys85, Cys250) was individually changed to 
serine.  The non-conserved cysteine derivatives were still active.  None of the 
individual C32S, C61S, C156S and C206S derivatives was able to methylate 
As(III).  However, the C32S and C61S enzymes retained the ability to methylate 
MAs(III).  These observations suggest that Cys156 and Cys206 play a different 
role in catalysis than Cys32 and Cys61.  Two other observations shed light on 
the pathway of methylation.  First, binding assays using the fluorescence of a 
single-tryptophan derivative indicate that As(GS)3 binds to the enzyme much 
faster than inorganic As(III).  Second, the major product of the first round of 
methylation is MAs(III), not MAs(V), and remains enzyme-bound until methylated 
a second time. 
Marapakala et al (2014) have reported new crystal structures of CmArsM 
with the bound aromatic arsenical phenylarsenite (PhAs(III)) at 1.80 Å resolution 
(PDB ID: 4KW7) and reduced roxarsone (Rox(III)) at 2.38 Å resolution (PDB ID: 
4KU9).  These organoarsenicals are bound to two of four conserved cysteine 
residues, Cys174 and Cys224.  The electron density extends the structure to 
include a newly identified conserved cysteine residue, Cys44, which is disulfide 
bonded to the fourth conserved cysteine residue, Cys72.  A second disulfide 
bond between Cys72 and Cys174 is observed in crystals with bound SAM (PDB 
ID: 4FR0).  In the SAM-bound structure, the helix containing Cys44 and Cys72 
reorients by nearly 6.5 Å closer to the As(III) binding site, relative to the 
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unliganded structure, which suggests that this movement leads to formation of 
the Cys72-Cys174 disulfide bond. 
Based on these observations, a novel disulfide cascade reaction scheme 
has been proposed for CmArsM, which may also be extended to CrArsM 
mediated catalysis (Figure 24).  The proposed reaction mechanism consists of at 
least two sequential disulfide bonds, the first between Cys46-Cys74, and the 
second between Cys74-Cys170 (Figure 24).  The catalytic cycle for the first two 
rounds of methylation can be summarized in eight steps.  1) In the first round of 
methylation, CrArsM binds As(III) in a series of three thiol transfer reactions from 
As(GS)3, which is the preferred substrate.  2) The methyl group of SAM is 
attacked by the arsenic lone pair, 3) which leads to formation of a positively 
charged pentavalent MAs(V) intermediate (Cullen, 2014).  4) The role of Cys46 is 
to provide electrons to reduce enzyme bound MAs(V) to MAs(III) and allow the 
next round of methylation.  By donating electrons to the arsenic, Cys46 becomes 
oxidized, forming a disulfide bond with Cys74.  5) The role of Trx is to reduce the 
disulfide bond, consistent with the traditional role of thioredoxins in facilitating 
reduction of protein cysteine disulfides by thiol-disulfide exchange.  Oxidized Trx 
is reduced by TR with electrons from NADPH.  MAs(III) remains strongly bound 
by the thiol pair Cys74-Cys170.  The disulfide bond is reduced with Trx, and 6) 
the enzyme undergoes the next round of methylation, forming a positively 
charged pentavalent DMAs(V) intermediate, 7) which is reduced to DMAs(III) by 
Cys74, forming a Cys74-Cys170 disulfide. 8) The disulfide is reduced by Trx,  
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regenerating the enzyme and releasing the major soluble product, DMAs(III), 
which is oxidized nonenzymatically to DMAs(V).  Thus, the substrates and 
products are all trivalent, as predicted by Hayakawa et al. (Hayakawa et al., 
2005), but the arsenic undergoes a cycle of oxidation and reduction, as 
hypothesized by Challenger (Challenger, 1947), but only when enzyme-bound.  
GSH and Trx are involved, but not as reductants of pentavalent intermediates.  
Instead, As(GS)3 serves as the arsenic donor to the enzyme, as hypothesized by 
Hayakawa et al. (Hayakawa et al., 2005), and Trx is a protein disulfide reductase 
(Holmgren, 1988).  The above hypothesis leads to many unanswered questions.  
Figure 24.  Proposed CrArsM reaction scheme 
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For example, how does ArsM use the glutathione conjugate, As(GS)3?  What is 
the role of the four conserved cysteine residues in arsenic binding and catalysis?  
How does the enzyme know whether the substrate is As(III), where Cys46 and 
Cys74 are required, and MAs(III), where they are not?  These questions may be 
resolved by an array of biochemical and biophysical experiments, including 
fluorescence measurements, isothermal titration calorimetry, site-directed 
mutagenesis as well as crystallization of additional orthologs in the presence of 
substrates and affectors. 
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CHAPTER IV 
Conclusion 
Life on earth originated in primordial environments where there were excess 
metals and harsh conditions.  The abundance of metals made it necessary for 
the first organisms to develop detoxification systems and modify the metals.  
Arsenic may have been present in very high concentrations as were other toxic 
metalloids (Sforna et al., 2014).  This is one of the reasons why arsenic related 
extrusion mechanisms are found in almost all the organisms from simple bacteria 
to humans. Arsenate mimics phosphate and thus enters organisms through the 
various phosphate uptake systems (Rosenberg et al., 1977).  The necessity for 
arsenic detoxification is common but organisms have evolved different 
mechanisms to realize this need.  The overarching theme of my research has 
been to elucidate the mechanisms of arsenic resistance, in particular how 
proteins bind As(III). In my dissertation research, I investigated two prominent 
arsenite detoxification mechanisms – ATPase-based extrusion and 
methyltransferase based biomethylation.  It is clear that ATPase-based extrusion 
is a mechanism to extrude arsenitefrom cells and hence produce resistance.  
However, there are contradicting views about the role of arsenic biomethylation 
in detoxification.  Several of the key events of arsenite biomethylation are not 
clear, and understanding them will help elucidate the role of this enzyme.  
 The ubiquity of arsenic in environment around us, both from 
anthropogenic sources and from human activities makes it  the most ubiquitous 
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environmental toxin and Group 1 human carcinogen according to the U.S. 
Environmental Protection Agency (EPA) and the Agency for Toxic Substances 
and Disease Registry (ATSDR) Priority List of Hazardous Substances 
(http://www.atsdr.cdc.gov/SPL/index.html). Humans with long-term chronic and 
occupational exposure to arsenic have been shown to have high prevalence to 
multi-organ cancers (Chappell et al., 1997; Kozul et al., 2009).  Both pentavalent 
As(V) and trivalent As(III) are toxic, with the latter more toxic than the former.  
Arsenolysis of arsenate compounds and the ability of arsenite to form strong 
bonds with thiol (-SH) groups are the major mechanisms for the action of arsenic. 
Arsenic enters cells adventitiously through uptake systems for phosphate 
(Willsky and Malamy, 1980), sugars (Liu et al., 2004) and other polyols (Sanders 
et al., 1997; Meng et al., 2004).  All identified extrusion systems of arsenic to 
date have been for As(III).  One of the most common As(III) extrusion system 
found in microorganisms is ArsAB pump, which was first discovered in the R773  
ars operon of E. coli (Mobley et al., 1983).  The arsA and arsD genes of ars 
operons are always found together, and their linkage suggests that they co-
evolved (Lin et al., 2006).  Later, ArsD was shown to a metallochaperone which 
transfers metalloid to ArsA ATPase (Lin et al., 2007; Yang et al., 2010). The 
presence of an arsD gene in addition to arsAB genes gives cells a competitive 
advantage over cells having only the arsAB genes while growing in sub-toxic 
concentrations of arsenic .  Additionally, cells expressing arsDAB accumulate 
less As(III) than those expressing only arsAB (Lin et al., 2006).    Although 
extensive research have been carried out on both the structural details of ArsA 
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and ArsD and their biochemical roles, limited work has been performed to 
understand and identify the surface residues of ArsA that interact with ArsD(Yang 
et al., 2011).   
In the second chapter, I studied the interaction between ArsA and ArsD. 
ArsD mutant K2A/K37A/K62A/K104A (4KA ArsD) does not interact with wild type 
ArsA in a yeast two-hybrid assay (Yang et al., 2011). I isolated three suppressor 
mutations in ArsA (Q56R, F120I, and D137V) through a e-PCR-based yeast two-
hybrid approach, which screened for mutants exhibiting increased interaction 
with wild type ArsD compared with 4KA ArsD (Figure 9).  Each of these three 
residues in ArsA (Gln56, Phe120, and Asp137) is located in NBD1.  Gln56 is 
situated in between the H3-S3 loop and exposed to solvent.  Phe120 is in the 
middle of H6 helix and surrounded by hydrophobic residues.  Asp137 is in the 
H7-S5 loop and exposed to solvent (Lin et al., 2006).  When wild type ArsD was 
added to an in vitro ATPase assay, the apparent affinity of wild type ArsA for 
As(III) increased 8.5-fold (Figure 11 and Table 4).  Addition of 4KA ArsD to the 
assay decreased the half maximal concentration for As(III) 1.6-fold.  Q56R ArsA 
showed basal ATPase activity similar to the wild type, which was stimulated 2.8-
fold in the presence of As(III).  Addition of either wild type or 4KA ArsD to the 
assay increased the affinity for As(III) 9- and 2-fold, respectively.  These results 
indicate that, although 4KA ArsD does not stimulate ArsA ATPase activity to the 
same degree as the wild type, it has a small but significant effect on the affinity of 
ArsA for As(III).  F120I and D137V ArsA showed a basal ATPase rate of 80 and 
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60 nnomol ATP hydrolyzed/min/mg protein, respectively.  The ATPase activity of 
either proteins was not stimulated by As(III); nor were any changes observed 
upon addition of either wild type or 4KA ArsD.  The difference in metalloid binding 
of wild type ArsA versus Q56R ArsA is not significant.  F120I and D137V ArsA do 
not show metalloid-stimulated ATPase activity, but their affinity for metalloid is 
unaffected by the mutations in antimony binding assay. A new in silico model 
(Fig. 13A) is proposed that supports our experimental data indicating that Q56R 
ArsA strongly interacts with wild-type ArsD and weakly with 4KA ArsD.  The new 
model also accommodates most of the ArsD residues that were shown to interact 
with ArsA by two-hybrid analysis (Yang et al., 2011). 
In the third chapter, I investigated the As(III) binding properties of the 
ArsM As(III) S-adenosylmethionine (SAM) methyltransferase. Methylation is a 
common biotransformation found in nature carried out by methyltransferase (MT) 
class of enzymes (Liscombe et al., 2012). Addition of a methyl group to an atom 
modulates its bioavailability, bioactivity and reactivity.  SAM is the most common 
source of the transfer of methyl group in MTs.  It is the most used substrate after 
ATP (Loenen, 2006).  SAM is the methyl donor to a wide variety of biological 
molecules like DNA, RNA, histones and proteins.  Low levels of serum folate, 
high levels of plasma homocysteine and polymorphisms in the MTHF receptor 
are implicated in SAM depletion and a wide range of diseases in humans 
(Coppen & Bolander-Gouaille, 2005, Ulrey et al., 2005).  Biomethylation of 
arsenite is widespread and occurs in all three domains of life, bacteria, archaea 
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and eukaryota (Ye et al., 2012, Sumi & Himeno, 2012, Zhu et al. 2014).  There 
are two major hypotheses about the pathway of arsenic methylation: 
Challenger’s pathway (Challenger, 1944) and Hirano’s pathway (Hayakawa et 
al., 2005).  Whether arsenic biomethylation is a pathway of arsenic detoxification 
is still being debated.  Some of the intermediate products, MAs(III) and DMAs(III), 
are more toxic than As(III) (Styblo et al., 2000, Sakurai et al., 2006, Hirano & 
Kobayashi, 2006).  However, the pentavalent intermediate products, MAs(V) and 
DMAs(V), are much less toxic than As(III) (Styblo et al., 2000), and the end 
product, TMA(III), is almost nontoxic (Cullen, 2005).  Understanding the 
molecular process of arsenic biomethylation is important in solving the paradox 
of As(III) biotransformation into potentially more toxic arsenic species.  
In this third chapter, I studied the molecular mechanism of arsenic 
biomethylation using biochemistry and biophysical approaches. A synthetic 
variant of CrArsM was constructed that retained the four conserved cysteines at 
position 46, 74, 170 and 220 of the primary sequence.  The remaining 13 
cysteines were altered to alanine.  Synthetic CrArsM was able to convert As(III) 
to mono- and dimethyl derivatives, although at a reduced efficiency of 25% than 
the wild type enzyme.  Synthetic CrArsM bound the triglutathione conjugate of 
As(III), As(GS)3, extremely rapidly compared to inorganic As(III), which is 
As(OH)3 in solution (Figure 20).  These  experiments indicated that the synthetic 
version behaved similarly as the wild type.  Diffraction quality crystals of synthetic 
CrArsM formed overnight at room temperature, allowed, he structure to be 
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resolved at 2.4 Å resolution. This was done collaboration with Charles 
Packianathan.  Cys74, Cys170 and Cys220 form the As(III) binding site.  This 
structure does not have As(III) bound to its active site.  Cys74 and Cys170 form a 
disulfide bond.  This structure is different from that of CmArsM (PDB ID: 4FS8), 
where no disulfide bonds were found in the native structure. A novel disulfide 
cascade reaction scheme has been proposed for CmArsM, which may also be 
extended to CrArsM catalysis (Figure 24).  The substrates and products are all 
trivalent, as predicted by Hayakawa et al. (Hayakawa et al., 2005), but the 
arsenic undergoes a cycle of oxidation and reduction, as hypothesized by 
Challenger (Challenger, 1947), but only when enzyme-bound.  
This study has isolated three ArsA mutants showing increased interaction 
with wild type ArsD - the Q56R, F120I and D137V ArsA mutants.  The new 
interaction model of the ArsA-ArsD interface suggests that the salt bridges 
alongwith the increased intermolecular hydrogen bonding contributes to the 
increased interaction between Q56R ArsA and wild-type ArsD.  The probable 
interactions according to this new model should be further studied by protein-
protein interaction assays or ATPase activity assays. . Attempts at crystallization 
of the increased interaction mutants have been unsuccessful in past.  These 
increased interactions may contribute to a stable co-crystal that can solve the 
interaction  interface. The increased hydrogen bonding  may provide the required 
interaction to keep the ArsA and ArsD together during crystallization. The 
synthetic CrArsM shows the involvement and requirement of 4 cysteines for 
biomethylation of arsenite by ArsM.  These four conserved cysteines should be 
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the target of future studies of arsenite binding and enzymatic methylation. The 
native crystal structure of CrArsM resembles the 4FS8 structure of CmArsM 
except for the disulfide bond between Cys74 and Cys170. Previously reported 
structures of CmArsM have shown disulfide bond between active site cysteines 
in the presence of organoarsenicals (4KW7 and 4KU9) or SAM (4FRD). The 
solved structure of native synthetic CrArsM is the first reported disulfide bond in 
native crystal structure. Future crystallization with ligands can shed light on the 
presence/absence of disulfide bonds when ligand is bound to synthetic CrArsM. 
A biochemical analysis of disulfide bond formation during enzyme catalysis can 
be performed to test the disulfide bond cascade hypothesis. 
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